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Abstract 
 
 Chitosan is one of the most widely studied materials in the field of drug delivery. 
Chitosan nanoparticles produced by ionic gelation can encapsulate macromolecular 
drug cargo. This work explores the potential of a specific chitosan molecule, ultrapure 
chitosan chloride, for oral vaccine delivery in vitro using polarised Caco-2 epithelial cells 
and in vivo using Balb/C mice.  
 
The chosen antigen used in the chitosan nanoparticles was ovalbumin (OVA). Work 
revealed an optimum concentration of 1 mg/ml of chitosan and OVA (i.e. 1:1 mass ratio), 
with addition of tripolyphosphate (TPP), for production of nanoparticles with a size of 
196.5 nm. The chitosan:OVA nanoparticles showed a zeta potential of +9.68 mv. SDS gel 
studies showed that OVA stability was not compromised following interaction with 
chitosan. Nanoparticle exposure to hydrochloric acid (HCl) and trypsin resulted in 
breakdown of OVA with HCl, while some protection was apparent with trypsin.  
 
Chitosan:OVA nanoparticles at 1 mg/ml displayed a good toxicity profile, measured 
through 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H- tetrazolium (MTS) and lactate dehydrogenase (LDH) assays. Transepithelial 
electrical resistance (TEER) data also support these findings, with TEER reversibility 
following application apparent. Application of chitosan:OVA nanoparticles to Caco-2 cell 
monolayers showed a reversible decrease in TEER, but a similar effect was seen with 
OVA solution and therefore a nanoparticle-specific effect could not be established in 
terms of tight junction opening. Chitosan:OVA nanoparticles however significantly and 
notably enhanced fluorescein isothiocyanate ovalbumin (FITC-OVA) permeability across 
Caco-2 monolayers when applied at 0.1 mg/ml (1:1 chitosan:OVA mass ratio). 
 
Studies which used Balb/c mice whereby chitosan:OVA nanoparticles were administered 
orally, did not show a convincing immune response. Specifically, IgG1, IgG2a and IgA 
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showed no response, while total IgG showed a small response with and without cholera 
toxin.        
 
This work therefore shows that a specific chitosan molecule is able to complex with OVA 
as a model antigen, producing sub 200 nm nanoparticles with a positive zeta potential. 
These systems showed clear effects in vitro, enhancing OVA permeability significantly, 
but in vivo response was not clear. This study illustrates that macromolecular absorption 
enhancement seen in vitro in intestinal models does not reliably predict in vivo immune 
response of vaccine delivery systems.  
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Chapter 1 
 
Introduction 
 
1.1 Oral vaccine delivery: possibilities and challenges 
1.1.1 The possibilities 
Infectious diseaseis the biggest threat for the human race and a cause of high 
morbidity rates. Up to 9.5 million people die because of infectious diseases per year 
(Kwon et al. 2013). Vaccinations have changed the face of medicine, causing the 
eradication of small pox and rinder-pest, and other diseases such as poliomyelitis to 
almost become extinct (Devriendt et al. 2012). Even though there are many oral 
vaccines currently on the market for diseases such as the oral polio vaccine, rota 
vaccine and an adenovirus vaccine; there are still disadvantages and problems that 
are not being addressed (Kwon et al. 2013).  
 
Administration of vaccines by injections is associated with a number of 
disadvantages. Firstly, the formulations require sterile and cold storage. Secondly, 
patient safety is one of the biggest concerns. Administration of injections is 
associated with risks, including injection site injury and infections, as well as high 
administration costs (requirement of healthcare professionals to administer) and 
poor patient compliance due to uncomfortable and painful administrations of 
vaccines.   
  
Oral delivery is the most desirable drug delivery method. Oral formulations used for 
vaccines may not need to be stored in cold stores which would be of benefit, 
especially in developing countries, this is due to the absense of an adjuvant e.g. a 
particular strain of virus (Devriendt et al. 2012). Patient compliance will also increase 
as patients will not have to be subjected to any pain or discomfort through invasive 
injections (Devriendt et al. 2012). 
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However, currently it is not possible to exploit the oral route for administration of 
vaccines. As protein-based actives, efficient oral delivery of vaccines requires 
specialist formulation solutions to overcome their poor stability in the 
gastrointestinal environment (e.g. presence of acid and proteolytic enzymes) and 
inability to interact with the mucosa in a way as to induce an immune response.  
 
A key requirement for oral vaccine delivery is activation of the IgA immune response. 
This would create an immune response in all the mucosa throughout the body and 
the entry points where a pathogen may enter, for example the oesophagus, 
urogenital tract or the gastrointestinal tract. This would be a first line defence 
against certain pathogens such as influenza, chlamydia, gonorrhea and measles (Kim 
et al. 2011).  
 
There are a few examples of mucosal vaccines to date which have been successful, 
increasing the motivation to make this for the majority of vaccines in the future. 
These include the Sabin polio vaccine, a vaccine against the rotavirus and vaccines 
against cholera and typhoid fever (Sharma et al. 2015). Due to most pathogens 
infecting humans at mucosal entries (nasal passages, oesophagus, trachea, 
gastrointestinal tract, etc.) the mucosa has been targeted as an effective site for 
immunity. The idea that if the mucosa is inoculated against certain pathogens there 
will then be systemic immunity throughout the body. The main route to combat 
pathogens infecting the gastrointestinal tract is to deliver the vaccine directly to the 
site. Delivering the vaccine to other mucosal sites would give a weaker response with 
less efficiency. However directing the vaccine towards the gut epithelium makes the 
response much more specific and robust (Kim et al. 2011).  
 
1.1.2 The challenges  
There are many challenges accompanying oral vaccine delivery. As briefly mentioned 
above, oral drug delivery requires that the drug molecule is able to withstand the 
environment of the digestive system. As the antigen is delivered via a mucosal route 
it is diluted due to the secretions (Sharma et al. 2015). Vaccines containing DNA, 
proteins and polysaccharides are prone to being degraded in the gastrointestinal 
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tract, resulting in a loss of bioactivity. The antigen used to activate the immune 
response also needs to be strong enough to create an IgA response throughout the 
body and in sufficient dose due to the large surface area of the gastrointestinal tract.  
 
The current absence of effective oral vaccines on the market is down to, the lack of 
antigens causing immunogenicity and challenges related to delivery of vaccines in 
their active form to the required site in the gastrointestinal tract. Poor uptake by 
epithelial cells and antigen presenting cells (APC) in the gastrointestinal tract, 
coupled with degradation en route, are key barriers contributing to this (Devriendt 
et al. 2012). The antigen needs to be released at the right time to achieve the highest 
maximum immune response possible. The antigen used must not be unstable or 
toxic in any way to humans, and must be compatible with the delivery system used.  
 
1.1.3 Oral drug delivery route 
The oral route is by far the most preferred method of drug administration. This route 
has several advantages: it is safe, inexpensive and is associated with high patient 
compliance, especially compared to injections. However, this route also faces 
several challenges (Finlay, 2001). It can be unpredictable and many factors can affect 
the absorption of the drug, including food, as well as acid and enzymatic breakdown. 
Large drug molecules may be inactivated as drugs delivered via the oral route face a 
harsh environment, which is rich in enzymes such as pepsin and trypsin and changing 
pH from a highly acidic environment (pH 1.5-3.5) to mildly alkaline (7-8). The drug 
then has to be absorbed through the gastrointestinal tract, which is lined by a 
mucosal barrier, which has evolved to be a selective barrier to material entering the 
body (Finlay, 2001).  
 
The mucosal surface is composed of the epithelium, covered by a mucus layer. Both 
the epithelium and the mucus layer present barriers to drug delivery.  These barriers 
will be discussed below with respect to drug delivery in general and specifically 
vaccine delivery.  
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      1.2 The digestive barrier 
1.2.1 The digestive system  
The physiological role of the digestive system is to convert food into nutrients, which 
are subsequently used by the body to obtain energy. The digestive system is made 
up of four main organs: the gastrointestinal tract, the liver, gallbladder and pancreas. 
The gastrointestinal tract is one long, hollow tube that runs from the mouth to the 
anus. It consists of the mouth, oesophagus, stomach, small intestine, large intestine, 
rectum and anus. The liver, gallbladder and pancreas are classed as the solid organs 
of the digestive system whilst the GI tract is classed as the hollow organ (Zhang et al. 
2014). The role of the mouth is to chew food down into  smaller and more managable 
pieces to ease with digestion. Saliva begins to breakdown food via a digestive 
enzyme amylase. The oesophagus transports the food broken down in the mouth to 
the stomach. Food is broken down further in the stomach via stomach acid and 
enzymes such as pepsin which degrades protein. The small intestine consisting of 
the duodenum, jejunum and ileum absorbs all of the nutrients needed from food 
into the bloodstream. The large intestine absorbs water and salts from the 
undigested food and produces a waste product (Yang et al. 2015). The liver and 
pancreas secrete hormones, whilst the gallbladder secretes bile used in the small 
intestine. The pH of the digestive tract varies from 1-7, with the stomach ranging 
from 1-3, the duodenum ranging between 6-6.5 and the large intestine ranging 
between 5-7 (Renukuntla et al. 2013).  
 
1.2.1.1 The digestive system and oral vaccine delivery  
Successful oral delivery of vaccines requires that the protein-based vaccine survives 
the harsh environment of the gastrointestinal tract, including low pH. Gastric acid is 
composed of many chemicals. HCl is secreted via the parietal gastric cells; these are 
the only exocrine cells within the body with such a function. A bicarbonate is also 
produced to help control the pH of the stomach and to act as a base (Dume et al. 
2013).  
 
The majority of drug absorption occurs within the small intestine, specifically across 
the villi which are responsible for absorbing food and protein (Renukuntla et al, 
2013). This region of the gastrointestinal tract is rich in enzymes such as trypsin, 
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endopeptidases, chymotrypsin and exopeptidases, which also break down any 
foreign proteins they encounter (Choonara et al. 2014).  
 
Both stomach acid and presence of enzymes within the gastrointestinal tract may 
cause loss of therapeutic activity by permanent denaturation or breakdown of the 
protein-based vaccine.  
 
1.3 Chitosan 
1.3.1 Source and physiochemical characteristics of chitosan  
Chitosan is a polymer that is derived from chitin, which is the second most abundant 
compound on the Earth and is found in the exoskeletons of many insects, the shells 
and skeletons of crustaceans and even in the cell walls of some fungi and algae 
(Casettari et al. 2011). Chitosan was chosen for its four main poperties; it is non- 
toxic to cells, it is mucoadhesive and bioadhesive, lastly it is biodegradable. 
Structurally, chitin is described as a homoglycan, which is a polysaccharide with 
repeating units of the same monosaccharide. It is structurally similar to cellulose, 
there is one key difference, cellulose is a polymer of D-glucose, whereas chitin is a 
polymer of N-acetyl-D-glucosamine. It is composed of β- 1,4- linked N-
Acetylglucosamine (GlcNAc) residues, each GlcNAc residue rotated 180° from the 
previous residue (Azevedo et al. 2011). The hydrogen bonds cause great tensile 
strength within the polymer. Chitosan is a popular derivative of chitin (Horton et al. 
2006) and is derived by the process of alkaline deacetylation or by enzymatic 
degradation (Casettari et al. 2011). The molecule is composed much like cellulose 
with a sugar backbone with β-1,4- linked D- glucosamine, the one difference being 
the hydroxyl group on the C-2 position is substituted by an acetyl amino group 
(Sunilkumar et al. 2014). The structure of chitosan is shown below in Figure 1.1. 
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       Figure 1.1: Chemical structure of polymer chitosan.  
 
The main differences in physical properties of cellulose and chitosan are integral to 
their uses within the scientific community. Chitosan is hydrophillic and dissolves in 
water and solvents at a ph of 6. Cellulose does not dissolve in water or solvents. 
Chitosan can also form complexes with particular metal ions such as iron and copper. 
Cellulose is the main component in a plant cell wall due to its tensile strength, 
however chitosan is a more flexible molecule in terms of its rigidity which is 
discussed below.  
 
The name chitosan itself actually covers a vast range of polysaccharides with 
different molecular weights, which ranges from 50-2000 kDa (Casettari et al. 2011). 
Chitosan also differs in the range of N-deacetylation, which ranges from 40-98%. 
Chitosan derivatives with a molecular weight of lower than 50 kDa are named 
oligochitosans (Casettari et al. 2011).  
 
Chitosan has a polyelectrolyte nature, with the repeated amino groups rendering 
the polymer with a positive charge at pH below its pKa (6.3). This provides chitosan 
with a strong electrostatic attraction to sialic acids e.g. in mucus, or a charge-
mediated attraction towards epithelial cells, which have a negative membrane 
charge. This attraction of chitosan to mucus and epithelial surfaces is termed 
mucoadhesion and bioadhesion, respectively. Both muco- and bioadhesion 
properties of chitosan contribute to its biomedical applications, especially in drug 
delivery (Casettari et al. 2011). 
 
1.3.2 Chitosan variability 
There are many varieties of chitosan on the market due to the fact that many 
variations of chitosan can be obtained depending on the way the chitosan was 
derived from chitin and the quality of the original chitin (Casettari et al. 2011). There 
are two types of chitin, alpha and beta. Alpha chitin has hydrogen bonds connecting 
the alternating polysaccharide chain in its structure; beta chitin does not have these 
hydrogen bonds. Alpha chitin is the more stable of the two and because of this it is 
less susceptible to de- acetylation than beta chitin. These produce a chain reaction 
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to the chitosan that is produced and therefore beta chitosan is considered more 
reactive, less rigid and has an increased solubility. The beta chitosan as a result is 
preferred to the alpha chitosan even if the molecular weights are similar. This is one 
of the main reasons why chitosan deacetylated from chitin will not be identical to 
perhaps another chitosan molecule from the same chitin derivative (Jung and Zhao, 
2012).    
 
These factors discussed above induce variations within the physiochemical and 
biomedical properties of chitosan, such as their ability to enhance the mucosal 
absorption of drugs (Casettari et al. 2011). Modifying the structure of chitosan is 
what causes the alteration in the properties of the molecule. There are three main 
groups that are altered; an amino group placed at C-2, a primary hydroxyl group at 
C-6 and a secondary hydroxyl group at C-3. Changing these major groups alters the 
molecules properties for biomedical applications. Therefore, the way the chitosan is 
processed chemically has a major impact upon the polymer. There are several ways 
chitosan is characterised depending on the property, including purity, physical 
appearance, molecular weight, viscosity and the degree of deacetylation. The 
different varieties of chitosan (e.g. CMC, TMC and PEG modified chitosan) have 
different intrinsic properties (such as an increased water solubility, increased 
biodegradability, absorption enhancement and increasing movement into the 
mucosa) causing them to be used in many applications in biomedical science 
(Sunilkumar et al. 2014). The variability of chitosan can be controlled via 
modification of the chitosan polymer to consistantly reproduce reliable nanosystems 
for drug delivery. These modifications are made to chitosans structure and once the 
'ideal' formulation has been modified. It is repeated reproducing a reliable 
nanosystem as a result.  
 
1.3.3 Chitosan derivatives 
One of the most commonly researched derivatives of chitosan is carboxymethyl 
chitosan (CMC). CMC has been studied in many areas including bio-imaging, wound 
healing, theranostics, in vitro diagnostics and gene therapy, as well the staple areas 
of drug delivery and tissue engineering (Upadhyaya et al. 2014). This is the most 
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popular and most widely used derivative of chitosan as it improves some of the 
characteristics of the parent molecule, chitosan.  
 
The advantages of CMC are; increased water solubility, increased biocompatibility, 
an increased moisture retention, increased biodegradability, increased antimicrobial 
and antifungal activity (Upadhyaya et al. 2014). CMC has shown to be more 
bioactive, e.g. increasing osteogenesis (Hsu et al. 2012). There are many different 
CMC formulations currently in research, including: microspheres, nanoparticles, 
aggregates, hydrogels, films and membranes (Upadhyaya et al. 2014).  
 
CMC shows potential for vaccine and protein delivery, including diphtheria toxoid 
and tetanus toxoid delivery, as well as insulin and bovine serum albumin delivery 
(Janes et al. 2001). One pitfall of using chitosan is the molecule’s insolubility at a pH 
higher than its own pKa which is estimated at 5.5-6.5 (Deng et al. 2013).  If it is being 
used for mucosal delivery in the lower intestine, chitosan will therefore not be 
soluble due to pH > 7. CMC has increased water solubility and is therefore more 
useful for mucosal drug delivery and tissue engineering (Upadhyaya et al. 2014).  
 
There are many different drug delivery formulations of CMCs. One is a hydrogel, 
which is a network of chitosan polymer chains that are hydrophillic and which can 
hold water up to five hundred times its own weight (Moghassemi et al. 2013). It is 
formed through the occurrence of cross linkages that are irreversible leading to the 
formation of the hydrogel (Upadhyaya et al. 2014). This gel permits the absorbance 
of water and related biocompounds and it also allows the drug it is carrying to be 
released via diffusion (Upadhyaya et al. 2014). Other formulations are in the form of 
microspheres, micelles or aggregates and nanoparticles. The latter are the most 
common and widely used formulation of CMCs (Moghassemi et al. 2013), with the 
ability to prolong the drugs half life which enhances the drugs therapeutic effect, 
increase the solubility of hydrophobic drugs and providing stimuli-responsive drug 
release potentially allowing minimisation of side effects (Upadhyaya et al. 2014).  
 
Another chitosan derivative is poly (ethyleneglycol) (PEG)-modified chitosan. PEG-
chitosan nanoparticles have been found to reduce the overall positive charge of the 
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nanoparticles and increase the biocompatibility (Janes et al. 2001). Furthermore, 
PEG chains on the nanoparticle surface cause extravasation of the particles and 
movement into the mucosa (Sharma et al. 2015) hence, potentially increasing the 
immune response.  
 
Trimethyl Chitosan (TMC) is another common, partially quarternised derivative of 
chitosan. The advantage and difference of TMC is that it has enhanced 
mucoadhesive effects and provides absorption enhancement at a neutral pH (Zhang 
et al. 2014). This is because the polymer has a permanent cationic charge and is more 
soluble in water with a wide pH range. This enables it to survive better in the harsh 
environment of the gastro intestinal tract and digestive system (Moghassemi et al. 
2015). Other benefits are higher antibody production when the antigen or adjuvant 
is attached to this chitosan derivative (Kwon et al. 2014),it is also tolerable in mice 
and less toxic than other polymers on the market, in addition to being biodegradable 
(Scheers et al. 2014).  
 
      1.4 Potential biomedical applications of chitosan  
Chitosan has three ideal properties that have attracted the attention of researchers 
within the drug delivery field. These are: low toxicity, biodegradability and 
biocompatibility. These are very important properties of the molecule and give an 
advantage and versatility for potential use in a broad range of biomedical 
applications, from wound healing to antimicrobial activity (Vllasaliu et al. 2010). 
However, the predominantly researched applications of chitosan include drug 
delivery, gene delivery and tissue engineering. 
 
1.4.1 Use of chitosan in drug delivery  
In terms of drug delivery chitosan has shown potential when used in solution or in 
the form of nano-sized delivery systems with the ability to deliver various drug 
cargoes, including nucleic acids (Upadhyaya et al. 2014), small molecules such as 
anticancer drugs (Fan et al. 2012) and protein drugs (Upadhyaya et al. 2014). 
Furthermore, these systems have been investigated for systemic delivery and for 
their ability to enhance drug delivery across mucosal surfaces. The capacity of 
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chitosan to facilitate drug delivery across mucosal membranes is attributed to its 
mucoadhesive properties and its ability to open the epithelial tight junctions.  
 
Tight junctions are structures that keep adjacent epithelial cells in close proximity 
with one another, hence creating a barrier to the movement of material, including 
drugs, between the cells (Vllasaliu et al. 2010). Tight junctions also act as an immune 
defence mechanism as it prevents bacterial toxins and particles from entering a cell 
(Wu et al. 2014). Tight junctions are composed of many integral proteins such as 
occludin, claudin and regulate proteins responsible for securing the proteins to the 
cytoskeleton (Yeh et al. 2011). The protein group claudin are known to hold the cells 
together between the tight junctions (Hsu et al. 2012). They also regulate the signal 
transductions entailing the tight junction permeability and cell differentiation (Yeh 
et al. 2011). Epithelial tight junctions are depicted in Figure 1.2.  
 
   
 
 
 
 
 
 
Figure 1.2: Epithelial tight junctions of Caco-2 cells. a) Transmission electron micrograph 
and b) confocal micrograph of Caco-2 monolayers immunostained for tight junction 
protein, Zonula Occludens-1 (ZO-1). a) Taken from Vllasaliu et al, 2011 and b) taken from 
Fowler,  2012.  
 
Both mucoadhesiveness and tight junction opening properties of chitosan are a 
result of the positive charge of the polymer (Vllasaliu et al. 2010). Positively charged 
amine groups on the backbone of the chitosan molecule interact with negatively 
charged integrins on the surface of the epithelial cell and the tight junctions (Hsu et 
al. 2013). Chitosan’s positive charge disrupts the integrin αVβ3 which has a negative 
charge causing the receptors to cluster on the membrane; this subsequently causes 
phosphorylation of Focal adhesion Kinase (FAK) and Src tyrosine kinases leading to 
the reaction with protein claudin-4 (CLDN4), which is integral in the permeability of 
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the tight junctions (Hsu et al. 2013). Chitosan redistributes the protein from the cell 
membrane to the cytosol, causing a disruption in the tight junctions ability to 
moderate permeability allowing macromolecules to enter the epithelial cells (Hsu et 
al. 2013). This process also causes a decrease in transepithelial electrical resistance 
(TEER) – a sign of tight junction opening (Yeh et al. 2011).  
 
Another method also discovered and thought to be a mechanism of tight junction 
opening is the activation of protein kinase C. The protein kinase C pathway is 
activated by phorbol myristate acetate, causing movement of some protein kinase C 
from the cytosol to the membrane. This disrupts the monolayer membrane 
permeability in the epithelial cells and therefore leads to the breakdown of the tight 
junctions (Smith et al. 2005). With the application of chitosan nanoparticles to cells, 
protein kinase C α was moved from the cytosol to the membrane, which leads to the 
disruption of tight junctions (Smith et al. 2005).  
 
The ability of chitosan to promote mucosal drug absorption is particularly important 
when considering macromolecules such as peptides and proteins, as well as 
oligonucleotides, which are not capable of crossing the epithelial surfaces due to 
their unfavourable physicochemical characteristics. Specifically, hydrophilic 
molecules larger than 1 kDa (which include most peptides, proteins and 
oligonucleotides) are poorly absorbed across the epithelial surfaces and are prone 
to degradation (e.g. from acid or enzymes) in some biological environments (e.g. 
stomach and duodenum). Researchers have therefore extensively looked into 
chitosan as a drug delivery molecule to aid the mucosal absorption of 
macromolecules (Zhang et al. 2014).  
 
1.5 Strategies for oral delivery of vaccines 
There are many delivery strategies for vaccines, including oral, nasal and 
intramuscular. This thesis is primarily focusing on oral drug delivery. Drug delivery 
strategies to enable oral delivery of vaccines have mainly centred around 
nanoparticles thus far this is due to several reasons; a reduction in toxicity, reduction 
in side effects of the drugs, prolongation of the antigen used, higher specificity and 
easy modification of the size and surface charge characteristics. Nanoparticles can 
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be synthesised using many different materials; however, researchers have taken a 
keen interest in chitosan, which is biodegradable and non-toxic material with 
mucoadhesive and tight junction opening properties (Hsu et al. 2012). Chitosan can 
be modified and altered, for e.g. PEG, TMC, and CMC,  allowing the polymer to 
exhibit enhanced characteristics compared to the original polymer.  
 
There are a number of different cells lining the gastrointestinal mucosa. From oral 
vaccine delivery point of view, M cells are of particular interest. M cells are located 
within the Peyer’s patches of the GI tract and represent only 5% of the human 
follicle-associated epithelium. M cells can deliver proteins and peptides from the 
lumen of GI tract to the lymphoid tissues, which results in an immune response. A 
high endocytic ability of M cells enables them to potentially absorb peptide drugs 
via oral delivery. They also have a high transcytotic ability which enables them to 
transport a wide variety of material including, macromolecules and drug delivery 
systems (e.g. nanoparticles and microparticles) (Renukuntla et al. 2013).  
 
                                    
Figure 1.3 Whole-mount immunohistochemical analysis of glycoprotein 2 (GP2) mature M 
cells (green) in the follicle-associated epithelia (FAE) of a mouse Peyer’s patch. Where V is 
villi. Taken from Mabbott et al. 2013. 
 
The commonly researched strategies to improve oral delivery of vaccines are similar 
to those employed for increasing the oral bioavailability of other classes of 
macromolecule-based drugs (e.g. peptides, antibodies and DNA). These typically 
make use of absorption enhancers, with a number of different such systems being 
researched.  
Chapter 1  Literature Review 
13 
 
 
Absorption enhancers work in several ways; they can temporarily disrupt the 
intestinal epithelial integrity (Wei et al. 2012), decrease mucus viscosity (Dünnhaupt 
et al. 2015), temporarily open epithelial tight junctions (Kondoh et al. 2012), increase 
epithelial membrane fluidity (Wei et al. 2012), prolong contact with the mucosal 
surface (Benektsdóttir et al. 2014) and inhibit drug degrading enzymes (Pereira de 
Sousa and Bernkop- Schnürch, 2014). There are several example systems within each 
of these categories. The use of one method over the other depends on the 
characteristics of the drug used (e.g. physicochemical properties), the chosen 
mucosal route and the therapeutics of the drug entailed. Absorption enhancers may 
also be used together, producing an enhancing effect on drug absorption. The many 
types of enhancer classes that have been researched so far are; chelating agents 
(Bishnu et al, 2014), surfactants (Daful, and Mackie 2014), fatty acids and their 
derivatives (Mori et al, 2004), bile salts (Holm et al. 2013) and polymers (Abramov et 
al. 2015).  
 
Chelators disrupt the epithelial intercellular tight junctions and decrease 
transepithelial electrical resistance (TEER) through a decrease in calcium levels. 
Surfactants affect the intracellular bilayers (order, fluidity and orientation) and may 
inhibit efflux mechanisms (SchrØder et al. 2014). Fatty acids and their derivatives 
increase the fluidity of the phospholipid membranes, with opening of tight junctions 
(Vllasaliu et al. 2010). Polymers may be mucoadhesive and may open the epithelial 
tight junctions (Renukuntla et al. 2013). An example of an  absorption enhancer is 
the polymer chitosan, which is the subject of this thesis.  
 
1.5.1 Nanoparticles used for oral vaccine delivery 
For the purpose of drug delivery, nanoparticles are drug carriers in the nano-scale 
dimension, between 1-1000nm, but more typically 50-200nm. The properties of the 
nanoparticles vary with the materials used to formulate them and the method of 
formulation (Abramov et al. 2015). Nanoparticles are employed in drug delivery to 
enable or enhance the therapeutic effect of drugs. For example, nanoparticles can 
be employed to selectively target certain tissues, protect the encapsulated drug and 
control the rate of drug release (Renukuntla et al. 2013). However there are several 
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challenges. There is difficulty in synthesising non- aggregated nanoparticles with 
constistantly desirable characterisitcs, the ambiguity of the distribution and 
targeting of nanoparticles and how nanoparticle characteristics influence the 
interactions with cells in the body. 
 
From oral drug delivery perspective nanoparticles are interesting as they provide 
potential advantages such as enhancement of drug stability, prolongation of the 
residence time in the GI tract, mucoadhesion, site specific drug delivery and 
enhanced cell uptake of the drug.  
 
Nanoparticles exploiting the changes in the pH across the GI tract are particularly 
attractive in nanoparticle-mediated oral drug delivery. These are based on 
nanoparticles that release the encapsulated drug depending on pH (SchrØder et al. 
2014). One example of this is poly (ɣ- glutamic acid) (ɣPGA)-chitosan nanoparticles, 
incorporating diethylene triamine pentaacetic acid (DTPA) as an agent known to 
disrupt the tight junctions in cells and inhibit intestinal proteases. These systems 
have been used in an attempt to improve oral delivery of insulin (Renukuntla et al. 
2013). DTPA was attached to poly (ɣ- glutamic acid) (ɣPGA) and nanoparticles were 
formed by mixing the ɣPGA-DTPA with a cationic chitosan. The nanoparticles formed 
were pH dependent and degraded above a pH of 7.0. When given to rats and viewed 
via confocal microscopy and scintigraphy (Daful and Mackie 2014), results showed 
that nanoparticles accumulated in the kidneys and bladder and the delivered insulin 
significantly reduced blood glucose levels for up to 4 hours after administration 
(Renukuntla et al. 2013).  
 
Another study used nanoparticles to target goblet cells to enhance oral absorption 
of insulin. Trimethyl chitosan chloride was combined with CSKSSDYQC (CSK) cell 
targeting peptide. This peptide improved the uptake of the nanoparticles across the 
GIT membrane; these modified nanoparticles showed a 1.5-fold increase in the oral 
bioavailability of insulin and an increased hypoglycaemic effect (Renukuntla et al. 
2013).   
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1.5.2 Chitosan nanoparticles in drug and vaccine delivery 
Chitosan nanoparticles are more stable in the gastrointestinal tract compared to 
other carriers such as liposomes (Deng et al. 2013), providing better protection of 
the drug or antigen that is encapsulated in the polymer. Liposomes are composed of 
a phospholid bilayer vesicle enclosing the chosen drug and an aqueous volume. It is 
negatively charged and cannot bind as easily to the intergrins on the epithelial gut 
surface. As it is composed of a phospholipid vesicle it decreases the availability of 
the drugs or antigen used. This makes chitosan a popular drug delivery polymer as 
exemplified by high research activity in the area. 
 
Chitosan also has the ability to gel when coming into contact with polyanions such 
as tripolyphosphate, which is caused by many intermolecular cross-linkages. The 
ionic gelation (also called ionotropic gelation) technique has been developed to 
create chitosan nanoparticles using tripolyphosphate (TPP). Upon mixing, chitosan 
and TPP interact through electrostatic interactions to create nanoparticles (Janes et 
al. 2001). The electrostatic interactions themselves occur between the positively 
charged amino groups of chitosan with the negatively charged groups of TPP. TPP is 
mainly used due to its non-toxic nature. Sometimes these nanoparticles are created 
with the drug, antigen or additional polymers added to the mix to create the system 
of interest (Calvo et al. 1997).  
 
The size of the chitosan nanoparticles produced by TPP ionic gelation method 
depends on the type of chitosan used (e.g. its molecular weight), chitosan:TPP ratio 
and the pH of the solution (Kang et al. 2015). Maintaining an overall positive charge 
on the surface of nanoparticles is thought to be important in order to preserve the 
chitosans ability to interact with negatively charged mucus and epithelial surfaces, 
as well as its ability to open the tight junctions (Chao et al. 2015). The TPP-mediated 
ionic gelation method produces chitosan nanoparticles under mild conditions - 
temperature and pH. This is important with protein-based therapeutics (e.g. 
vaccines), preventing damage to the therapeutic during the formulation process. 
The negative side to this however is that ionic gelation is associated with a wide 
particle distribution size and low stability, though, as mentioned above, the type of 
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chitosan used often dictates this, with a low molecular weight chitosan seemingly 
producing smaller nanoparticles (Fan et al. 2012).    
 
Chitosan nanoparticles promote oral drug and vaccine delivery in a number of ways. 
Before considering ways in which chitosan nanoparticles may improve oral delivery, 
it is worth mentioning that materials in general cross the gastrointestinal epithelium 
via the paracellular route, which is the space between adjacent epithelial cells 
whereby tight junctions form ‘kissing points’ between cells, or through the 
transcellular pathway. The latter takes place through epithelial cells and may be due 
to passive absorption, active transport and endocytosis. Passive transport is the 
facilitated movement of material from an area of high concentration to low 
concentration. This relies strongly on the ability of the molecules to diffuse through 
the membrane. Active transport is the opposite of passive transport: it transports a 
material against a concentration or electrical gradient and requires energy to take 
place. Finally, endocytosis requires energy and involves the molecule being engulfed 
by cells and transported through the membrane, which may or may not be released 
on the other side (in a process known as transcytosis) (Choonara et al. 2014).  
 
In the paracellular pathway, material crosses the aqueous channels within epithelial 
tight junctions (‘paracellular corridor’). These channels are selective to small 
molecules (<100- 200 kDa) (Choonara et al. 2014) and with molecules over 700 Da 
bioavailability starts to decrease significantly (Renukuntla et al. 2013). 
Macromolecules, including vaccine antigens, therefore cannot utilise this route to 
traverse the intestinal epithelium. The paracellular space equates to 0.01-0.1 cm2 
surface area of the intestine therefore in reality does not normally contribute 
significantly in intestinal absorption of orally administered drugs.  
 
Nanoparticles are probably likely to cross the GIT via the transcellular pathway. It is 
the more common method of drug absorption than the paracellular route. This is 
due to properties of the nanoparticles and the size of the antigen chosen. There are 
a number of ways in which nanoparticles in general are internalised into cells. These 
are: phagocytosis, pinocytosis and receptor-mediated endocytosis (Choonara et al. 
2014). Phagocytosis involves the engulfment of nanoparticles up to 10µm in 
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diameter by macrophages and neutrophils. Pinocytosis is a type of cellular uptake 
mechanism this is caused by the absorption of nanoparticles alone and in solution. 
This happens within all cell types and with smaller nanoparticles (Renukuntla et al. 
2013). During endocytosis the nanoparticles associate with the cell membrane, e.g. 
via receptors. The nanoparticles are then internalised into vesicles into the cell 
cytoplasm. The nanoparticles subsequently may be degraded by lysosomes or 
escape the degradative route and travel to other organelles and/or released by 
exocytosis. In epithelial cells such as enterocytes nanoparticles may travel from the 
intestinal lumen into systemic circulation via transcytosis (Choonara et al. 2014).  
 
       
 
 
      1.6 Project aims  
 The introduction suggests the polymer chitosan can intergrated into vaccine 
delivery due to its popular physical and chemical properties. The aim of this project 
is to investigate the potential of a specific chitosan product, namely ultrapure 
chitosan chloride which previously has shown significant absorption-enhancing 
potential in vitro, to deliver vaccines across the intestinal epithelium. The initial work 
of this project will focus on formulation and characterisation of chitosan 
nanoparticles before studies commence in vitro using a Caco-2 epithelial cell line. 
Following physiochemical characterisation, formulations will be tested for their 
toxicity. Concentrations with an acceptable toxicity profile will be further tested for 
their ability to: 1) open epithelial tight junctions in vitro, 2) enhance the permeability 
of OVA in vitro and 3) elicit a systemic immune response in vivo following oral gavage 
immunisations using Balb/C mice.  
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Chapter 2 
Materials and General Methods 
 
2.1 Materials 
2.1.1 Cells, culture media, media components and cell solutions 
Caco-2 cells were obtained from the European Collection of Cell Cultures (ECACC) and 
used from passages 57-88 (passage used in terms of the level of cell differentiation). All 
of the following was purchased from Sigma Aldrich (UK); the medium used during the 
culture of this cell line was dulbeco's modified eagle's medium (DMEM) (with added 
110mg sodium pyruvate, 4500mg glucose and L- glutamine), other media components 
used were antibiotic and antimycotic solution (which contains 10,000 units of penicillin, 
10 mg of steptomycin and 25 µg amphotericin) and foetal bovine serum (FBS). Hank’s 
balanced salt solution (HBSS) (with sodium bicarbonate, without phenol red), was used 
as a solution for cell uptake, transepithelial electrical resistance (TEER) and permeability 
studies. Phosphate buffered saline (PBS), trypsin (EDTA added, 0.25% w/v) and dimethyl 
sulfoxide (DMSO) were used in the process of cell rinsing, detachment from flask surface 
(during cell ‘passaging’) and cryopreservation of the cells, as referred to in section 
2.2.1.2.  
 
A standard bottle of DMEM (500 ml) was supplemented with 55 ml of FBS and 5 ml of 
antibiotic/antimycotic solution; containing penicillin, streptomycin and amphotericin, 
before being applied to the cells. This was developed in the university labs and from this 
point onwards the supplemented DMEM will be referred to as cell media.  
2.1.2 Plasticware and glassware 
Transwell permeable supports (also referred to as filters) of 12 mm diameter and 0.4 
µm pore size and sterile, clear and black 96 well polystyrene microplates (tissue culture 
treated) were both obtained from Costar (USA). Cell culture flasks (75 cm2, canted neck 
with vented caps) were obtained from Nunclon (Denmark) and sterile pipettes which 
were used for general use whilst maintaining Caco-2 cells were from Sarstedt 
(Germany). Sterile centrifuge tubes were from Sigma Aldrich (UK). Small glass cylinders 
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(50 ml) and small 20 ml disposable scintillation glass vials were obtained from 
Fisherbrand (UK). A metal set of different sized spatulas were purchased from RSG 
Solingen (Germany). Duran bottles (varying in size from 100 ml to 1000 ml) used for 
making up stock solutions were purchased from SCHOTT. Vivaspin™ sample 
concentrators (molecular weight cut of 1,000,000 Da) were from Sartorius (Germany).  
 
2.1.3 Cell toxicity assay reagents  
3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent, which is commercially known as  'CellTiter 96 AQueous One 
Solution Cell Proliferation Assay' was obtained from Promega (USA). For the LDH (lactate 
dehydrogenase)  assay,  the 'pierce LDH cytotoxicity assay kit' (Thermo Scientific, USA) 
commercial kit was used according to the manufacturer’s instructions. 
 
2.1.4 Chemicals 
Different types of Ovalbumin (OVA) were used: Fluorescein isothiocyanate (FITC)-
labelled ovalbumin (OVA) (FITC-OVA, 3 moles dye/mole), purchased from Molecular 
Probes (USA); non- labelled OVA was purchased from Sigma Aldrich (UK) and endotoxin-
free OVA (EndoGrade® was purchased from Cambridge Bioscience (UK). Ultrapure 
chitosan chloride of 213 kDa average molecular weight (‘Protasan UP CL 213’) was 
obtained from Novamatrix (Denmark). Other reagents used were; tripolyphosphate 
(TPP), Triton X-100, 2-(N-morpholino)ethanesulfonic acid (MES), paraformaldehyde and 
fluoroshield with DAPI. These were all purchased from Sigma-Aldrich (UK).  
 
Tween surfactant and hydrochloric acid (HCl) were bought from Fisher Scientific (USA). 
Bovine serum albumin (BSA), sodium carbonate (Na₂CO₃), sodium bicarbonate 
(NaHCO₃), heparin and ammonium persulfate (APS) were all obtained from Sigma 
Aldrich (UK). Acrylamide was obtained from BIORAD (USA) and glycine, tris, sodium 
dodecyl sulfate (SDS) and tetramethylethylenediamine (TEMED) were all obtained from 
Melford (UK). 
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2.1.5 Antibodies 
Goat anti-mouse IgG H & L horseradish peroxidase (HRP) pre-absorbed was purchased 
from Abcam (UK), goat anti- mouse IgA-HRP was obtained from Invitrogen and goat anti- 
mouse IgG1- HRP was purchased from Southern Biotech (USA). 
 
 
2.2 Methods 
2.2.1 Maintenance of the cells  
2.2.1.1 Maintenance of Caco-2 cells in culture flasks 
Caco-2 cells were routinely maintained in 75 cm2 flasks placed in incubators with 5 % 
CO2, 95 % relative humidity, with a temperature of 37 °C until 70-80 % confluency. Cell 
medium was replaced every 2-3 days in the culture flasks, which was done by aspirating 
out the old media and replacing it with 12 ml of fresh medium. All cell culture buffers 
(PBS and HBSS) were also pre-warmed to 37 °C prior to contact with the cells and all 
protocols involved with handling Caco-2 cells in culture were performed aseptically. 
When at least 70-80 % confluent, cells were ‘passaged’ or seeded into a 75 cm2 flask as 
detailed below.  
 
The following protocol was used for cell passaging (or subculturing); old medium was 
aspirated out and the cells were washed with 5 ml of PBS twice, making sure to remove 
all of the old medium and any dead cells there may be, using a gentle swirling motion. 
Washing the cells is an important step in the process as left over FBS present in DMEM 
inactivates trypsin, making it less efficient for cell detachment. Once the cells had been 
washed, the PBS was aspirated out and 3 ml of trypsin was added and gently swirled 
ensuring the trypsin covered all the cells; the flask was then incubated although the time 
length is dependent on the cell line and the confluency within the flask. For Caco-2 at 75 
% confluency this is approximately 10-15 minutes. After incubation the cells were 
completely detached from the bottom of the flask, at which point 9 ml of fresh medium 
was added to inactivate the trypsin. After giving the flask another gentle swirl, 1.5 ml of 
cell suspension was added to a new flask, corresponding to 1:6 ‘split ratio’. 10.5 ml of 
fresh media was then added to the newly created flask and the flask clearly labelled with 
the cell line, passage number, user name and date. The flask was then placed back in 
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the incubator for further culture. The medium used for culturing Caco-2 cells was 
DMEM; for supplements added to the medium refer to section 2.1.1.  
 
2.2.1.2. Frozen storage of cells  
Cells were cultured until they were confluent and then detached from the bottom of the 
flask using the method previously described in section 2.2.1.1. However, after the fresh 
medium was added to the flask to deactivate the trypsin, the cell suspension was 
centrifuged at 2500g for 5 minutes to create a pellet at the bottom of the centrifuge 
tube. The supernatant was then aspirated out and the cell pellet re-suspended in 1 ml 
of fresh medium containing 100 µl of DMSO (i.e. DMSO was used at 10 % v/v). The 
suspension was then added to a sterile cryovial, which was clearly labelled with the 
relevant details (name, date, cell line and passage number). This process was repeated 
for each confluent flask, creating one cryovial from one flask. These were then placed 
into a freezing container, 'Mr Frosty' in a -80 °C freezer. The cells were stored at -80 °C 
for up to 3 weeks. After 3 weeks the cells were then transferred into the liquid nitrogen 
storage tank; the cells were stored in liquid nitrogen for as long as required.    
 
2.2.1.3. Cell revival 
The relevant cryovials were removed from the liquid nitrogen storage tank and placed 
in an incubator to thaw for 2-5 minutes at 37 °C. The cell suspension was then 
transferred to a flask with 16 ml of fresh cell medium in. Note, one cryovial was 
transferred into one cell culture flask for cell growth.  
 
2.2.1.4. Culture of cells on transwells 
Caco-2 cells were cultured until they were confluent (75-95 %) and kept at 37 °C with 5 
% CO2 levels. It is standard practice to culture cells on transwell filters when performing 
studies in vitro in drug absorption studies. Cells were detached from flasks using the 
previously described method in section 2.2.1.1. While the cells were incubating with 
trypsin, medium was added to the transwell filters. 0.5 ml was added to the apical 
chamber and 1.5 ml was added to the basolateral chamber. This was done so when the 
cells were added to the apical chamber they had a more stable environment and were 
more likely to adhere to the plastic membrane. A volume of cell suspension 
corresponding to 1x105-2x105 cells (usually 20 µl) was added to the apical transwell 
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compartment. The cells were then cultured in normal cell culture conditions until they 
formed a polarised/differentiated monolayer, which was approximately 21 days with 
regular replacement of cell medium (every 2-3 days).  
 
2.2.2. Measurement of transepithelial electrical resistance (TEER) 
Measuring the TEER is a very important technique in epithelial cell culture, this gives an 
indication of cell monolayer integrity, cell polarity and epithelial tight junction function. 
TEER was measured using an epithelial voltohmmeter with ‘chopstick’ electrodes (World 
Precision Instruments, USA). One electrode is longer than the other to account for the 
depth of basolateral and apical transwell compartments. The electrodes measure the 
electrical resistance to the ion flux (e.g. Ca2+, K-, Na+ and Cl-) across the epithelial cell 
monolayer. This method has become the universal method within epithelial in vitro 
research to measure the formation and function of tight junctions, as well as cell 
membrane integrity, it is convenient, reliable and does not damage the cells used. 
 
Figure 2.1 demonstrates how to use the equipment. Before the cells were measured the 
probes were placed in 70 % ethanol to sterilise them. This was for approximately 20-25 
minutes. The longer probe was placed in the basolateral transwell compartment and the 
shorter probe was placed in the top, apical compartment. Note that TEER was measured 
before any replacement of medium or cell passaging took place; this was because we 
noticed that the TEER temporarily changes when the cell medium is replaced from the 
transwell filter. TEER was measured before any studies with polarised Caco-2 
monolayers took place to establish the integrity, confluence of the cells and the 
formation and function of tight junctions.     
 
TEER values reported in this research have taken into account the area of the cell layer, 
which is assumed the same as the area of the transwell membrane. These values are 
expressed as Ωcm2. Background resistance was also measured on all cell-free transwell 
filters (typically 100 Ωcm2): this was subtracted from the TEER values taken for cells 
throughout this thesis.    
 
 
 
Epithelial 
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Figure 2.1 Representation of the equipment used to measure the TEER of the cell layers. 
 
2.2.3. Preparation of chemicals  
2.2.3.1. Tripolyphosphate 
10 mg of tripolyphosphate (TPP) was weighed out and mixed with 10 ml of hank's 
balanced salt solution (HBSS) and mixed until TPP dissolved. 
2.2.3.2. 2-(N-Morpholino)ethanesulfonic acid hydrate (MES hydrate)  
195 mg of 2-(N-Morpholino)ethanesulfonic acid hydrate (MES hydrate) was added to 
100 ml of HBSS and mixed until the MES hydrate had dissolved in the solution. This 
created 10 mM HBSS with a pH of 6.0.  
 
2.2.3.3. Wash buffer (PBSx20/0.05 % tween surfactant)   
2.5 ml of tween surfactant was added to 250 ml phosphate buffered saline at a 
concentration of x20. These were then added to 5 litres of distilled water. 
 
2.2.3.4. Assay diluent  
10 g of bovine serum albumin (BSA) was added to 1 litre of water with 5 PBS tablets. 
These were mixed and dissolved before 3 ml of tween surfactant was added. Lastly, 3.7 
g of EDTA was added to the solution.  
Chopstick 
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s 
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2.2.3.5. Preparation of pH 9.6 carbonate buffer 
16 ml of 0.2 M stock solution of sodium carbonate was added to 34 ml of sodium 
bicarbonate stock solution. 150 ml of distilled water was then added to dilute to a pH of 
9.6.   
 
2.2.3.6. Resolving buffer 
Resolving gel buffer consisted of 1.5 M tris pH 8.8 and 0.4 % SDS. 
 
2.2.3.7. Preparation of Stacking buffer 
Stacking gel buffer consisted of 0.5 M tris pH 6.8 and 0.4 % SDS. 
 
2.2.3.8.resolving gel (12%) 
The resolving gel was made up as follows: 4.1 ml of autoclaved mQ water, 3 ml of 
resolving buffer (see 2.2.3.6), 4.8 ml of 30 % acrylamide/bis. 
 
2.2.3.9. Stacking gel (4%) 
The stacking gel was made up as follows: 3 ml of autoclaved mQ water, 1.3 ml of stacking 
buffer (see 2.2.3.7), 0.67 ml of 30 % acrylamide/bis and 5 µl of bromophenol blue to 
visually see the wells. 
 
2.2.3.10. Running buffer 
Running buffer consisted of 115.2 g glycine, 24 g tris and 2 L of deionised water. 
 
2.2.4. Cell toxicity studies 
2.2.4.1. MTS cell metabolic activity assay 
The MTS assay measures the metabolic activity of the cell once the sample has been 
applied. The cell viability is measured at the end of the assay. Tetrazolium in the MTS 
reagent is reduced to a coloured formazan product via the presence of the electron 
acceptor phenazine ethyl sulphate in metabolically active cells. This dye is visible once 
the assay has finished. Cells were seeded onto a 96-well, clear multiwell plate (cell 
culture treated) and were left to incubate with DMEM at 37 °C 5 % CO2 for 24 hours for 
the cells to establish attachment on the bottom of the plate and grow. The cell medium 
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was aspirated out, making sure the pipette tip did not touch the bottom of the 96 well 
plate so not to damage the cells. The samples tested were then applied at differing 
concentrations (0.1 mg/ml, 0.05 mg/ml, 0.025 mg/ml and 0.0125 mg/ml) in HBSS. A 10 
% v/v solution of triton X-100 in HBSS was prepared as a positive control and finally HBSS 
alone was used as a negative control. 100 µl of each sample was placed into 6 wells for 
repeats (i.e. n=6) and placed into an incubator at 37  °C/5  % CO2 for 3 hours. After 3 
hours the samples were aspirated from the wells and 100 µl of cell medium was applied 
to each well. 20 µl of MTS reagent was then added to all the wells. The 96-well plate was 
placed in an incubator at 37 °C/5 % CO2 for 2 hours, according to the manufacturer’s 
protocol. When the plate had finished incubating, the absorbance at 490 nm was 
measured using tecan.     
 
The relative cell metabolic activity (%) was calculated using the following equation:  
 
Relative metabolic activity =
𝑆−𝑇
𝐻−𝑇
  𝑋100 
 
Key: 
 S is the absorbance of cells incubated with tested samples  
 T is the absorbance of cells incubated with triton X-100 
 H is the absorbance of cells incubated with HBSS 
 
2.2.4.2. Lactate dehydrogenase (LDH) assay 
The LDH assay measures cell membrane integrity by measuring the release of the 
enzyme lactate dehydrogenase, this is only released when cell membranes are 
compromised via toxicity. This differs from the MTS assay by measuring different aspects 
of the cells. Cells were seeded onto a clear, flat-bottomed 96 well plate 48 hours before 
the assay. Cell medium was aspirated from the 96 well-plate and samples differing in 
concentrations and dissolved in HBSS were then applied to each well. A 10 % solution of 
triton X-100 in HBSS was prepared as a positive control and finally HBSS alone was used 
as a negative control. 100 µl of the required samples were applied to the cells with 
repeats of 6 and left to incubate at 37 °C/5 % CO2 for 3 hours. 50 µl of each sample was 
then transferred to another clear flat-bottomed 96-well plate. The assay was conducted 
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according to manufacturer’s instructions. 50 µl of the LDH reaction mixture was then 
added to each sample and mixed using a pipette. The plate was then left at room 
temperature for 30 minutes and covered with foil. 50 µl of stop solution (1 M acetic acid) 
was then applied to each well and mixed by gentle tapping. The absorbance was 
measured at 490 nm by tecan.  
 
The LDH release was calculated as the percentage relative to the controls using the 
following equation:  
 
Relative LDH release = 
𝑆−𝐻
𝑇−𝐻
 𝑋100 
 
Key: 
 S is the absorbance of cells incubated with the tested samples 
 H is the absorbance of cells incubated with HBSS 
 T is the absorbance of cells incubated with triton X-100 
 
2.2.5. TEER studies   
All TEER studies were conducted on cells that were cultured on transwell inserts for at 
least 21 days. Cell medium was aspirated out of each well and HBSS was applied to each 
well (warmed to 37 °C) and the TEER was measured (method described in section 2.2.2.) 
The transwell plate was then placed in an incubator for 40-45 minutes for the cells to 
adjust to the change in environment (replacement of medium with HBSS). The samples 
tested were dissolved in HBSS. The HBSS from the apical side was aspirated out and 0.5 
ml of each sample was applied to the wells. Three wells were used per sample and HBSS 
was used as a negative control. TEER was measured, as described in section 2.2.2., at 
time 0 and then every 30 minutes for 3 hours (30, 60,  90, 120, 150 and 180 min).  
   
2.2.6. Nanoparticle permeability study 
Transwell-cultured cells with a minimum TEER of 900 Ωcm2 (Chen et al. 2015) were 
deemed suitable for cell permeability studies. TEER measurements were taken before 
permeability studies took place as a reassurance of the cellular tight junctions formation 
and the integrity of the Caco-2 cell monolayers. HBSS was warmed in a water-bath to 37 
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°C. The cell medium was aspirated out and replaced with HBSS (1.5 ml in the basolateral 
side and 0.5 ml in the apical chamber); the transwell plate was placed in an incubator at 
37 °C/5 % CO2 for 40-45 minutes. When the cells had adjusted, tested via TEER, the HBSS 
was aspirated from the apical side and replaced with 0.5 ml of the test sample at 
differing concentrations (0.1 mg/ml, 0.05 mg/ml, 0.025 mg/ml and 0.0125 mg/ml). At 
time 0, 100 µl of the sample was taken from the basolateral chamber and placed in a 96-
well black plate. The sampled solutions were replaced with equal volumes of HBSS and 
the transwell was placed back in the incubator at 37 °C 5 % CO2. Basolateral samples 
were further taken every 30 minutes for 3 hours, repeating the method just described. 
Translocation of the tested sample was quantified by fluorescence using tecan (488 nm 
excitation and 520 nm emission). 
 
These measurements were analysed by converting the fluorescence into concentrations 
and then into amounts (micrograms). This was done through the calibration curves (0.1-
0.000195 mg/ml).  
 
Permeability is expressed as the apparent permeability coefficient (Papp), which was 
calculated using the following equation: 
 
 
 
 
Key: 
 Papp is the apparent permeability 
 dQ is the amount of drug 
 dt is the drug transport transported by time  
 A is the membrane surface area 
 C0 is the donor concentration at time 0 
        
2.2.7. Cell fixation for microscopy  
Cells were fixed after the completion of permeability studies. The sample was aspirated 
from the apical and basolateral membranes and cells washed twice with PBS. 100 µl of 
paraformaldehyde was then applied to the apical membrane chamber and left for 5 
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minutes. After the cells had been fixed the paraformaldehyde was removed and PBS was 
placed into the apical and basolateral chambers. The transwell plate was then covered 
with foil and placed into the fridge until needed for imaging.     
  
2.2.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- PAGE) 
To make the electrophoresis gels, the following method was used: a glass plate and a 
white plate were put together with a spacer of 1 mm in between the plates. It was made 
sure that the plates were levelled off to prevent any leaks from occurring. The plates 
were bolted into the gel caster and dH2O was poured between the plates to ensure there 
were no leaks. The gel caster was tipped upside down to remove all of the dH2O.   
 
Next, 12 % gels were made. Two sterilins were used; one labelled resolving gel, one 
labelled stacking gel. Stacking gel concentrates all of the samples into one band so all of 
the samples run at the same time once they pass into the running buffer. The resolving 
gel seperates the samples based on their molecular weight. Once the resolving gel (see 
section 2.2.3.8.) and the stacking gel (2.2.3.9.) was prepared, 100 µl of ammonium 
persulphate (APS) and 16 µl of tetramethylethylenediamine (TEMED) was added to the 
resolving gel. APS and TEMED are used to catalise the polymerisation of acrylamide/ 
bisacrylamide. This forms a mesh which ultimately forms the gels that are used. 10 % 
APS solution was made fresh that day by adding dH2O to APS powder. Once APS and 
TEMED were added to the gel, the gel started to set. The dH2O was removed from the 
gel casters and the resolving gel was applied first; a small amount of residue was left at 
the bottom of the sterilin so it was clear when the gel polarised. Resolving gel was 
poured between the clear and white plates, 2/3 of the way up. A small amount of dH2O 
was added on top of the resolving gel to make sure the resolving gel was level. After the 
resolving gel had set, 50 µl APS and 16 µl of TEMED was added to the stacking gel. The 
stacking gel was then added to the gel casters. The stacking gel was filled to the top of 
the plates and a well caster was placed between the plates to create the wells. This took 
10-15 minutes to set.  
 
The gels were then clipped in place in a tank and running buffer was then added to the 
plates. Once samples were applied to the wells, the gels were wired up to an electric 
current and run at 150 mv for 1 hour. One reference ladder was added per gel. 
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2.2.9. Polyacrylamide gel staining and imaging 
When the gels finished running, the stacking gel was cut off and placed in a pot. 
Coomassie blue stain was applied for 10-15 minutes. The excess stain was poured back 
into the bottle and the gel was then immersed in dH2O. Destain (already made up) was 
then applied for 10-15 minutes. The gel was rinsed in dH2O and DE Stain was applied 
again and left overnight. The next day the gel was compared to the reference ladder.  
 
2.2.10 Nanosight 
The equipment used a technique called nanoparticle tracking analysis (NTA) this is a 
combination of both dynamic light scattering (DLS) and brownian motion to get a true 
result of the particle size and concentration in liquid suspension. The laser is shone 
through the sample chamber and the particles in the path of this beam scatter light for 
the person using the equipment to visualise the particles. There is a video camera 
attached to capture the particles move in brownian motion. 
 
Following formulation, chitosan:OVA nanoparticles were diluted 1:100-1:200 in dH2O or 
HBSS before size measurement in Nanosight. The sample was then inserted into the 
Nanosight top plate using a small syringe. Size analysis was carried out using the in-built 
Nanosight control user interface software. A range of concentrations (1 mg/ml, 0.5 
mg/ml, 0.25 mg/ml and 0.125 mg/ml) were used to find the ideal size (200nm).    
 
2.2.11 Confocal Microscopy 
Caco-2 cells were first fixed using the above method in section 2.2.7. A slide with 
transwell filter was then prepared using the following method; a scalpel was placed in 
absolute ethanol for approximately 30 minutes to sterilise it before use. This was then 
used to carefully cut the transwell membrane, which was then carefully removed with 
tweezers and placed on a slide, cell side up. DAPI nuclei stain was then applied to the 
cells. The cell-populated transwell membrane was covered with a coverslip before 
confocal imaging. A Leica SP8 confocal microscope was used for imaging.  
 
Image analysis was carried out using the in-built confocal control user interface 
software (Leica SP8) and digital imaging system.  
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2.2.11 Statistical Analysis 
Statistical comparisons were performed by ANOVA in multiple group comparisons. 
Values of p<0.05 were considered statistically different. 
 
2.3 References 
1. Chen, S., Einspanier, R. and Schoen J. (2015). Transepithelial Electrical Resistance 
(TEER): a Functional Parameter to Monitor the Quality of Oviduct Epithelial Cells Cultured 
on Filter Supports. Histochemistry and Cell Biology, 144(5): 509-15. 
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Chapter 3 
Formulation and Characterisation of Chitosan:OVA 
Nanoparticles 
 
3.1 Introduction 
 
Chitosan is an organic biomaterial derived from the exoskeleton of many crustaceans. It 
has shown many potential applications in biomedicine, including use in formulation drug 
delivery systems such as microparticles and nanoparticles with the ability to cross 
mucosal membranes (Raftery et al. 2015).  The capacity of chitosan to facilitate drug 
delivery across mucosal membranes is attributed to its mucoadhesive properties and its 
ability to open the epithelial tight junctions in cells. Tight junctions are structures that 
keep adjacent epithelial cells in close proximity with one another, hence creating a 
barrier to the movement of material between the cells (Vllasaliu et al, 2010). Tight 
junctions also act as an immune defence mechanism as it prevents bacterial toxins and 
particles from entering the body (Wu et al. 2014). 
 
Chitosan nanoparticles are often researched and used within the drug delivery sector to 
facilitate drug delivery across mucosal membranes, including those of the 
gastrointestinal tract (Kheradmand et al. 2015). There are several advantages to 
chitosan nanoparticles, for example: low toxicity, high drug loading efficiency, simple 
preparation, prolonged circulation in the blood, amenability to controlled release 
(chemical stimulus such as pH) and targeted and controlled delivery (Zhang et al. 2015). 
Nanoparticles are an effective way to improve drug delivery and prevent the 
degradation of the therapeutic agent (Madureira et al. 2015). 
 
Although chitosan has been previously researched for its potential for mucosal vaccine 
delivery, this work set out to determine the potential of nanoparticles formulated from 
ultrapure chitosan chloride specifically, as a chitosan salt which has previously shown 
significant potential for mucosal protein delivery in  vitro (Vllasaliu et al. 2010). The work 
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further investigates the action of chitosan nanoparticles in vivo, as well as the 
mechanisms by which chitosan nanoparticles facilitate transepithelial delivery of 
ovalbumin (OVA) as a model antigen.   
 
This chapter will detail the formulation and characterisation of chitosan:OVA 
nanoparticles, which were initially formulated by the ionic gelation method, followed by 
characterisation studies. Characterisation of nanoparticles was conducted with respect 
to size and charge of nanoparticles, their ability to complex and release the payload 
(OVA) on contact with a negatively charged macromolecule (heparin) and capability to 
protect OVA from acidic and enzymatic degradation.  
 
3.2 Methods 
3.2.1 Preparation of nanoparticles  
3.2.1.1 Preparation of chitosan:OVA nanoparticles 
Chitosan (‘Protasan UP CL 213’) nanoparticles were prepared in different concentrations 
and chitosan:OVA ratios in order to identify an optimal formulation ‘recipe’ producing 
nanoparticles of desirable characteristics to be used in further studies. Chitosan was 
used in different concentrations: 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml and 0.125 mg/ml, 
whilst OVA was kept constant at 1 mg/ml. First, stock solutions of 2 mg/ml of chitosan 
in dH2O and 2 mg/ml OVA in dH2O were prepared. As a chloride salt, the specific chitosan 
used in this project (‘Protasan UP CL 213’) dissolves in dH2O with continuous stirring in 
approximately 20 minutes. Once dissolved chitosan was mixed with OVA creating a 1 
mg/ml concentration (1:1 ratio).  
 
Following mixing of chitosan and OVA solutions, TPP solution (1 mg/ml) (see section 
2.2.3.1) was then added via a syringe and needle and added to the chitosan:OVA 
solution in a slow, drop-wise manner. TPP was added until the solution started to look 
opalescent which indicated the formation of nanoparticles (nanoparticle solution should 
look between figures 3.1 b and c). Care was taken to avoid adding TPP in excess as this 
resulted in formation of visible particulate matter, probably as a result of excessive 
nanoparticle aggregation and/or precipitation (if this was encountered, the samples 
were discarded (see figure 3.1 d for reference). Samples were diluted in dH2O as 
appropriate to the following ratios: 1:2, 1:4 and 1:8. 
Chapter 3                                    Formulation and Characterisation of Chitosan:OVA Nanoparticles  
38 
 
 
a)                                          b)                               c)    d) 
 
 
Figure 3.1 a) Chitosan and OVA mixed solution with no TPP, b) Chitosan:OVA nanoparticles 
with a few drops of TPP, c) Opalescent chitosan:OVA nanoparticle solution, d) Aggregated 
particulate matter due to too much TPP.    
 
Three different types of OVA were used in this project. For TEER, cytotoxicity and 
nanoparticle characterisation studies, unlabelled OVA was used. For permeability 
studies, OVA release and confocal microscopy, fluorescently labelled, FITC-OVA, was 
purchased and employed to enable OVA permeability quantitation through fluorescence 
measurement and visualisation with confocal microscopy. In vivo studies utilised 
unlabelled, endotoxin-free OVA.   
 
3.2.1.2 Preparation of chitosan nanoparticles 
Chitosan (‘Protasan UP CL 213’) nanoparticles were used in the same concentrations and 
ratios as chitosan:OVA nanoparticles for comparison in future studies (1 mg/ml, 0.5 
mg/ml, 0.25 mg/ml and 0.125 mg/ml). First a stock solution of 2 mg/ml of chitosan in 
dH2O was prepared. TPP solution (1 mg/ml) was then added via a syringe and needle 
and added to the chitosan solution in a slow, drop-wise manner.  
                
3.2.2 Nanoparticle size characterisation using Nanoparticle Tracking Analysis (‘Nanosight’) 
Nanoparticle size characterisation was conducted using Nanoparticle Tracking Analysis 
by Nanosight LM10 HS instrument (Malvern, UK). This was an essential part of the 
nanoparticle formulation, establishing optimal ratio of chitosan and OVA.   
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3.2.3 Nanoparticle surface charge characterisation using Zetasizer  
Nanoparticle surface charge characterisation was conducted using Dynamic Light 
Scattering (DLS) by a Zetasizer Nano ZS (Malvern, UK). Particles suspended in a liquid will 
move in accordance with brownian motion. The light scatters off particles in the liquid 
reflecting onto other particles. The velocity in which the particles move is measured by 
the zetasizer calculating the surface charge of the suspension. This is explained by the 
Stokes-Einstein equation: 𝐷 =
𝑘𝑇
6𝜋𝑅ƞ
 
Key:  
 D is diffusion coefficient 
 K is the Boltzmann constant 
 T is the temperature 
 ƞ is the viscosity of the solution 
 R is the hydrodynamic radius of the particle 
 
Chitosan and chitosan:OVA nanoparticles were formulated as described previously 
(section 3.2.1.2 and 3.2.1.1) and diluted in dH2O or HBSS/MES (pH 6.0) to compare the 
difference in surface charge. Four measurements were taken and the average zeta 
potential was calculated by the instrument.  
 
3.2.4 Characterisation of OVA release from chitosan:OVA nanoparticles  
1 mg/ml samples of chitosan:OVA nanoparticles (1:1 mass ratio) were prepared, as per  
section 3.2.1.1, using FITC-OVA. This particular formulation was used as a comparison 
for permeability studies in vitro. 100 µl of chitosan:OVA nanoparticles were placed into 
6 wells in a 96 well flat bottomed plate and the fluorescence was read using a Tecan 
Infinite M200 Pro plate reader (Tecan Group ltd, Switzerland). The excitation 
wavelength at 488 nm and the emission wavelength at 520 nm. These were covered 
with foil until further needed. 1 ml of heparin was applied to one scintillation vial of 
chitosan:FITC-OVA nanoparticles previously prepared and left for 30 minutes at room 
temperature (approximately 22 °C). After 30 minutes 1 ml of chitosan:FITC-OVA 
nanoparticles exposed to heparin and control chitosan:FITC-OVA nanoparticles were 
processed for membrane unltrafiltration by using vivaspin centrifugal concentrator 
tubes (MWCO 1,000,000 Da) and centrifuging for 20 minutes at 3000 rpm. Following 
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centrifugation 100 µl of the filtrate was transferred to a 96 well flat bottomed plates. 
The fluorescence was then read by Tecan and the results recorded.      
 
3.2.5 Characterisation of OVA stability in chitosan:OVA nanoparticles 
Stability of OVA within chitosan:OVA nanoparticles was tested following exposure to 
hydrochloric acid (HCl) and trypsin 10x is a 2.5% solution of 1:250 trypsin. Comparison 
of OVA solution and chitosan:OVA nanoparticles after exposure to HCl or trypsin was 
made. HCl and trypsin play a key part within the digestion of food. Trypsin is one of the 
digestive enzymes which assists in food breakdown within the stomach. This study was 
designed to test the stability of OVA to two of the materials found within the digestive 
system which would present a great barrier to protein stability. Chitosan:OVA samples 
were exposed to HCl or trypsin, followed by exposure to heparin in order to release OVA 
before analysis of OVA stability by SDS PAGE. All samples were prepared at 1 mg/ml, 
samples were prepared as follows; 
 
Sample Formulation 
1. 1ml Chitosan:OVA nanoparticles after exposure to heparin.  
2. 1ml Chitosan:OVA nanoparticles after exposure to HCl and 
heparin.  
3. 1ml Chitosan:OVA nanoparticles after exposure to trypsin 
(concentration 10x) and heparin.  
4. 1ml OVA in HBSS at pH7 (control).  
5. 1ml OVA after exposure to HCl at pH1-2.  
6. 1ml OVA after exposure to trypsin (concentration 10x).  
 
Table 3.1 Samples prepared for OVA stability characterisation study.  
 
Chitosan:OVA nanoparticles were prepared (see section 3.2.1.1) for samples 1, 2 and 3. 
OVA solution, using HBSS/MES, was prepared for samples 4, 5 and 6. 100 µl of 70 % HCl 
was added to 900 µl of chitosan:OVA nanoparticle solution in sample 2 and OVA solution 
in sample 5. 10 µl of trypsin (concentration 10x) was added to 990 µl of chitosan:OVA 
nanoparticles in sample 3 and OVA solution in sample 6. These samples were incubated 
for one hour at room temperature. Note that sample 2 and sample 3 were exposed to 
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HCl (sample 2) and trypsin (concentration 10x) (sample 3) first. After 30 minutes samples 
5 and 6 were also exposed to HCl (sample 5) and trypsin (concentration 10x) (sample 6), 
all samples were left for a further 30 minutes at room temperature. Room temperature 
was used because the HCl was not stable enough to heat. While the samples were 
incubating, a 5 mg/ml solution of heparin was prepared in dH2O. When samples 2 and 3 
had finished incubating (HCl and trypsin, respectively), 1 ml of 5 mg/ml heparin solution 
was applied (1:1 heparin:chitosan mass ratio) to samples 1, 2 and 3 for 30 minutes. Note, 
samples 2 and 3 finished incubating 30 minutes before samples 5 and 6, this was so 
samples would all finish incubating at the same time. 
 
After incubation samples 1, 2 and 3 (exposed to heparin) were filtered using Vivaspin 
membrane ultrafiltration tubes with centrifugation at 3000rpm for 15 minutes. The 
filtrate was collected and placed in a labelled Eppendorf tube. All samples were analysed 
by SDS-PAGE (see section 2.2.8).  
 
 
3.3 Results  
3.3.1 Chitosan:OVA and chitosan nanoparticle characterisation 
3.3.1.1. Nanoparticle sizing using DLS (dynamic light scattering) 
 
A preliminary dynamic light scattering study using a 1 mg/ml chitosan solution (in 
HBSS/MES, ph 6.0) alone was performed. The data showed no peaks suggesting that 
there is no nanoparticle formation without the addition of TPP. 
                          
 
 
 
 
 
 
 
Figure 3.2 is a control study, in this instance that of 1 mg/ml OVA solution alone in 
HBSS/MES. The figure shows positive signal suggesting presence of particulates of 75 
Chapter 3                                    Formulation and Characterisation of Chitosan:OVA Nanoparticles  
42 
 
and 135 nm (mode = 77.4 nm). It is unclear where this signal originates from in the 
sample, as OVA protein in solution is significantly smaller (6 nm). However, it could be 
due to aggregation of OVA, there is a high aggregation of OVA to increase OVA to 77.4nm 
in size.  
 
 
 
                                                                                                 
      
 
 
 
 
 
 
 
Figure 3.2 Control experiment: 1 mg/ml OVA solution. 3 repeat samples were formulated for 
repeats. 
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Figure 3.3 is another control experiment of 1 mg/ml chitosan and OVA solution (no TPP) 
to determine the size in suspension of a mixture of chitosan and OVA without the 
addition of TPP. The figure shows the presence of a number of particle population sizes, 
resulting in an overall mode of 292.5 nm. Figure 3.2 and 3.3 demonstrates there are no 
particles without the addition of TPP to the chitosan:OVA complex and therefore TPP is 
needed for nanoparticles to form.     
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Control experiment: diameter of 1 mg/ml solution of chitosan and OVA (no TPP). 3 
repeat samples were formulated for repeats. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 shows 1 mg/ml solution of chitosan:OVA nanoparticles, 1:1 mass ratio. Data 
shows a dominant peak of particle species with 195 nm diameter, with smaller particle 
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populations of larger size, producing an overall mode of 196.5 nm. It is worth noting that 
chitosan:OVA nanoparticles display a smaller size and particles where a large proportion 
is of a narrow size range compared to physical mixture of OVA and chitosan without TPP 
(above). This could be explained by TPP-induced ionic gelation creating smaller and 
more compact particles.  
 
Note that the 1:1 chitosan:OVA mass ratio of nanoparticles was used in subsequent 
experiments, in vitro and in vivo due to optimal nanoparticle size (196.5 nm).  
 
 
 
Figure 3.4 Size analysis of 1 mg/ml chitosan:OVA nanoparticles (1:1 mass ratio) in dH2O. 3 
repeat samples were formulated for repeats. 
 
 
 
 
 
 
 
 
 
Figure 3.5 shows nanoparticles of 1:2 chitosan:OVA mass ratio. The graph has a broad 
peak suggesting polydisperse nanoparticle sample with a mode of 301.5 nm. Figure 3.5 
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shows multiple peaks of high concentration in the sample rather than one concentration 
predominating, this was also shown infigure 3.4, as well as  a higher mode. Lower 
content of chitosan therefore leads to higher polydispersity. There is less chitosan to 
interact ionically with TPP, therefore there are more free TPP molecules and free OVA 
in the solution.  
 
 
                                                 
Figure 3.5 Size analysis of 1:2 mass ratio chitosan:OVA  nanoparticles in dH2O. 3 repeat 
samples were formulated for repeats. 
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Figure 3.6 shows nanoparticles of 1:4 chitosan:OVA mass ratio. Data again suggests a 
polydisperse sample with multiple peaks of high concentration as opposed to one 
concentration predominating (as in figure 3.4). Mode is higher at 329.7 nm.  
 
 
 
        
                                      
 
 
 
 
 
 
 
Figure 3.6 Size analysis of 1:4 mass ratio chitosan:OVA  nanoparticles in dH2O. 3 repeat 
samples were formulated for repeats. 
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Figure 3.7 shows nanoparticles of 1:8 chitosan:OVA mass ratio. The mode is 380.9 nm 
and multiple peaks also contribute to a large proportion (y axis shows high 
concentration) in the sample rather than one concentration predominating, as in Figure 
3.4.  
 
We can conclude from Figures 3.4-3.7 that the optimal chitosan:OVA mass ratio for 
further studies is 1:1, which is why we took this ratio forward for future experiments.  
 
       
 
 
 
                                                
 
 
 
 
Figure 3.7 Size analysis of 1:8 mass ratio chitosan:OVA  nanoparticles in dH2O. 3 repeat 
samples were formulated for repeats. 
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Figure 3.8 shows 1 mg/ml, 1:1 ratio of chitosan:OVA nanoparticles in HBSS/MES (pH 6.0). 
This figure was studied to show the size in the biological cell solution used for in vitro 
studies. The data in fact shows a smaller mode of 126.1 nm in HBSS/MES than in dH2O 
which has a pH of 7.0. This factor could be a contributing cause to the displayed 
monodispersity. The data also shows that a single particle population with 125 nm 
diameter dominates in the sample, i.e. even though the sample is polydisperse (other 
peaks are apparent), a single population size is dominant. The standard deviation is also 
relatively small at 35.2 nm.    
Note only a 1:1 ratio of chitosan:OVA nanoparticles were tested in HBSS. Once the ideal 
size was found in dH2O, the nanoparticles were tested in HBSS.  
 
                                                     
 
 
 
 
 
 
 
 
 
Figure 3.8 Diameter of 1 mg/ml chitosan:OVA nanoparticles in HBSS. 3 repeat samples were 
formulated for repeats. 
 
 
3.3.1.2. Surface Charge  
Table 3.2 compares the surface charge of chitosan:OVA nanoparticles against chitosan 
nanoparticles (without OVA) in HBSS and dH2O. It is apparent that samples have a lower 
surface charge in HBSS compared to dH2O. Chitosan:OVA nanoparticles in HBSS had a 
surface charge at +9.68 mv in comparison to chitosan:OVA nanoparticles in dH2O 
(+37.9mv). HBSS acts as a buffer and neutralises the surface charge with negatively 
charged counter ions in the solution which surround the nanoparticles lowering the 
positive charge. The zeta potential is lower in chitosan:OVA systems, with chitosan 
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nanoparticles (no OVA) having a zeta potential of +13.1. This is again expected as OVA 
has a slightly negative charge, decreasing chitosan’s positive surface charge. In table 3.2 
the most stable sample is chitosan nanoparticles in dH2O with a surface charge of +41.9 
mv. The least stable sample is chitosan:OVA nanoparticles in HBSS with a surface charge 
of +9.68 mv. However OVA and HBSS needed to be within the nanoparticle complex, as 
the antigen used and the cell solution used for in vitro studies.  
Sample (0.5 mg/ml) Zeta potential (mv) 
Chitosan:OVA nanoparticles in HBSS  +9.68 mv  
Chitosan nanoparticles in HBSS  +13.1 mv  
Chitosan:OVA nanoparticles in dH2O +37.9mv  
Chitosan nanoparticles in dH2O +41.9mv  
Table 3.2 Zeta potential comparison of chitosan:OVA nanoparticles against chitosan 
nanoparticles in HBSS and dH2O.  
 
3.3.1.3 Characterisation of OVA release from chitosan:OVA nanoparticles 
The release of OVA from chitosan:OVA nanoparticles was tested by the addition of a 
highly negatively charged molecule, heparin. It was envisaged that with heparin having 
a significantly higher negative charge than OVA, it would interact electrostatically with 
the positively charged chitosan and ‘release’ OVA from the nanoparticles. Figure 3.9 
shows data related to OVA release from formulated chitosan:OVA nanoparticles. The 
stoichiometry of dye:protein used within this study is 3:1. The fluorescence of 1:1 mass 
ratio of chitosan:FITC-OVA nanoparticles (1 mg/ml each) was measured before and after 
OVA release, which was triggered by exposure to heparin and membrane ultrafiltration. 
Control chitosan:OVA NP and chitosan:OVA NP bars indicate the sample before vivaspin-
mediated filtration, without exposure to heparin. There is not a significant decrease 
between the two bars. The average fluorescence intensity for control chitosan:OVA 
nanoparticles alone is 6904 and the average for chitosan:OVA nanoparticles before 
exposure to heparin is 7175. The filtrate and chitosan:OVA NP + heparin filtrate bars 
represent the samples after membrane ultrafiltration. The fluorescence intensity of the 
filtrate bar of chitosan:OVA nanoparticles without heparin treatment is dramatically 
lower – 499 – compared to 6904 before filtration. This suggests that 499 of OVA is lost 
following filtration of chitosan:OVA nanoparticles, most likely excess unincorporated 
OVA, but the majority remains incorporated in chitosan:OVA nanoparticles, which are 
not able to pass through membrane pores of vivaspin. With chitosan:OVA nanoparticles 
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exposed to heparin and then filtered through vivaspin membranes, the fluorescence 
intensity decreases following filtration, but this decrease, from 7175 to 6232.16 is not 
as notable as with control samples not exposed to heparin. The high fluorescence 
intensity of the filtrate of the sample treated with heparin suggest successful release of 
OVA from chitosan:OVA nanoparticles, which is then able to cross vivaspin membrane 
pores in the ultrafiltration process. If this study expressed FITC-OVA:chitosan 
complexation efficiency from fluorescence/membrane ultrafiltration study (Figure 3.9), 
then a high efficiency of 93 % is obtained (fluorescence after filtration/fluorescence 
before filtration assuming a linear fluorescence versus concentration). The 
concentration of OVA in figure 3.10 for control chitosan:OVA NP is 0.85, after 
centrfugation and filtration it is -0.29. This has a decrease of -0.56 in concentration. 
When heparin is added there is an increase in OVA concentration. Chitosan:OVA NP was 
0.90 the concentration after was 0.73. There was a relatively small decrease of 0.17.     
 
 
Figure 3.9 Release of OVA from chitosan:OVA nanoparticles, tested following exposure to 
heparin and membrane ultrafiltration (using vivaspin tubes). The statistical test ANOVA was 
used in this figure *** signifies P=0.0002; * signifies P= 0.0356. 
 
  
3.3.1.4 Stability of OVA to acid and enzymatic exposure analysed by SDS PAGE 
OVA has a molecular weight of 45kDa. Figure 3.10 shows that samples (with the 
exception of S2 and S5) have a band between 55kDa and 40kDa on the SDS gel.Therefore 
these bands belong to OVA. Sample 1 - chitosan:OVA nanoparticles exposed to heparin, 
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shows a  45 KDa band of medium size. Sample 2 - chitosan:OVA nanoparticles exposed 
to HCl and heparin shows no band due to degradation by HCl. Sample 3 - chitosan:OVA 
nanoparticles exposed to trypsin (concentration x10) and heparin shows a thin 45KDa 
band, this demonstrates some degration by trypsin although not as much as samples 2 
and 5. Bands below the main 45KDa band are visible, although faint showing further 
breakdown of OVA. Sample 4 - OVA alone (positive control) is the thickest band on the 
gel (45KDa). Sample 5 - OVA exposed to HCl shows there is no band. The HCl breaks 
down the OVA leaving no protein visible. Sample 6 - OVA exposed to trypsin 
(concentration x10), shows a moderately sized 45KDa band. Smaller bands below the 
main band are visible showing the continuous breakdown of OVA. The bands are more 
pronounced (more visible) in comparison to sample 3.  
 
 
  
 
Figure 3.10 SDS Gel showing the stability of OVA when exposed to hydrochloric acid or trypsin 
in solution or in chitosan:OVA nanoparticles. S1 - chitosan:OVA nanoparticles exposed to 
heparin, S2 - chitosan:OVA nanoparticles exposed to HCl and heparin, S3 - chitosan:OVA 
nanoparticles exposed to trypsin (concentration x10) and heparin, S4 - OVA alone (positive 
control), S5 - OVA exposed to HCl and S6 - OVA exposed to trypsin (concentration x10). 
 
  
3.4 Discussion 
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This chapter describes the formulation and characterisation of chitosan:OVA 
nanoparticles. Since OVA was used in this research as a model antigen, it was important 
to characterise the formulation, including the size of the nanosystem produced, surface 
charge, the ability of OVA to be released from the system and the ability of nanoparticles 
to protect OVA from acid and enzymatic degradation. The latter is crucial if oral delivery 
of vaccines is to become a viable approach. 
 
Nanoparticle size is a very important factor, it determines cell uptake (SchrØder et al. 
2014). Nanoparticles of several chitosan to ovalbumin ratios were formulated producing 
different systems, which were tested to determine optimal nanoparticle formulation via 
nanoparticle tracking analysis. We considered an optimal system to be one which 
produces nanoparticles in the size range 100-300 nm and low polydispersity.  
 
It was found the chitosan:OVA ratio is an important determinant of nanoparticle size. 
Even though the ratio of chitosan:TPP is also critical in terms of size control, we found it 
was the chitosan:OVA ratio which exerted a larger control on size. A decrease in chitosan 
left OVA and TPP in excess instead of binding to chitosans positive amine groups which 
decreased the formation of the compact, stable nanoparticle complexes. This caused 
aggregation of OVA causing an increase in polydispersity. Therefore these parameters 
were focused on. We noted the TPP requirement in the system was minimal in order to 
produce nanoparticles. This is in agreement with previous research, which found that 
low TPP content can lead to production of smaller nanoparticles (SchrØder et al. 2014). 
The more TPP that was added to the solution, the more cloudy the solution became due 
to the nanoparticles aggregating. TPP can bind up to five particles of chitosan creating 
larger particles and aggregates within the solution (Antoniuo et al. 2015).  
 
The chitosan:OVA nanoparticles formulated in this work had a relatively low 
polydispersity. It has been reported that the higher the molecular weight of the chitosan 
the higher the increase in polydispersity, explained by the higher molecular weight 
chitosan agglomerating more quickly than the lower molecular weight chitosan and thus 
increasing the polydispersity within the solution (Antoniuo et al. 2015).  
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The 1:1 mass ratio of chitosan:OVA nanoparticles produced a size of 196.5 nm in 
diameter. As this ratio decreased, the size of the nanoparticles, as well as polydispersity, 
increased. The size of nanoparticles produced in this study is similar to a study reporting 
systems of 210 nm (Nallamuthu et al. 2015). In dH2O different nanoparticle ratios had a 
larger polydispersity than in HBSS. A 1:1 ratio of chitosan:OVA nanoparticles were tested 
for size in HBSS and producing monodispersity. This is because there are negatively 
charged counter ions within the solution making the nanoparticles much more compact 
and therefore more monodisperse. 
 
The measurement of the zeta potential is also important with nanosystems, especially 
considering a link between the nature of the surface charge, toxicity and biological 
effects of the systems. Surface charge also is a good predictor of the colloidal stability of 
the system, meaning there is no aggregation at a significant rate from the nanoparticles. 
Chitosan has a positive charge of around + 35 to + 40 mv (Gan et al. 2005) for a high 
molecular weight chitosan, which is why it is bioadhesive and mucoadhesive to epithelial 
and mucosal cells. The surface charge of the chitosan:OVA nanoparticles prepared in 
this work is lower compared to values typically reported for two reasons. One being that 
OVA lowers the surface charge of the nanoparticles as itself has a slight natural negative 
charge. Ovalbumin holds a positive charge from pH 1.0-4.5 however as the pH increases 
the zeta potential decreases. From a pH 6.0-6.7 OVA has a charge of -20 to -25 mv (Niu 
et al. 2014). The biological medium, HBSS, also lowers surface charge, this being due to 
the negatively charged counter ions within it. As demonstrated from table 3.2 the 
chitosan:OVA nanoparticles in HBSS have a surface charge of + 9.68 mv, and 
chitosan:OVA nanoparticles in dH2O have a surface charge of + 37.9 mv. This is 
comparable to other studies: chitosan:OVA nanoparticles ranged between +18- +25 mv 
(SchrØder et al. 2014). Alprazolam-loaded chitosan-egg albumin nanoparticles had a 
zeta potential of + 7.88 mv (Jana et al. 2013). This is comparable to this data and again 
shows a protein such as OVA decreases the zeta potential of chitosan nanoparticles. 
Overall this has an impact upon the colloidal stability of the nanoparticles, decreasing it. 
  
Heparin was used to 'release' OVA from the chitosan:OVA nanoparticle complex in figure 
3.9. This was shown, membrane ultrafiltration prevented FITC-OVA within 
chitosan:FITC-OVA nanoparticles from passing through filter pores, while, following 
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incubation with heparin, this was no longer the case (filtrate showed high fluorescence 
intensity). It was important to test the ability of chitosan to release the payload as to 
achieve a therapeutic effect. The incorporated cargo has to be released in the ileum on 
the M cells to induce the desired immune response.  
A study where FITC-OVA was used in the preparation of nanoparticles, went through 
similar methodology as ours (Amidi et al. 2006). Nanoparticles were centrifuged at 
18,000g for 20 minutes and the fluorescence of the supernatant was read before and 
after centrifugation, to measure how much uncomplexed OVA is present in the system. 
Their results showed a high nanoparticle loading capacity, as suggested by a low free 
OVA value in the supernatant and this was attributed to the negative charge of OVA 
bonding to the positive charge of the chitosan nanoparticles. The study also found the 
highest loading capacity and loading efficiency concentration was 0.5 mg/ml, a loading 
capacity of 55 % and a loading efficiency of 45 % (used in this work) was found at a 
concentration of 1 mg/ml (Amidi et al. 2006).  
 
The stability of OVA within chitosan:OVA nanoparticles was also tested using SDS gels to 
analyse whether the stability of OVA is compromised when 1) complexed into 
chitosan:OVA nanoparticles, and 2) when chitosan:OVA nanoparticles are exposed to 
harsh chemical conditions such as those of the gastrointestinal tract. Figure 3.10 sample 
1 shows chitosan:OVA nanoparticles where OVA was released with heparin treatment, 
demonstrates a clear band attributed to OVA. This suggests that the complexation of 
OVA to chitosan and subsequent release does not compromise OVA stability, which is a 
key requirement of the delivery system. Samples 2 and 5, treated with HCl however 
showed no bands on the gel, pointing to complete breakdown of OVA. The data 
therefore implies that chitosan:OVA nanoparticles at 1:1 mass ratio are not capable of 
protecting OVA upon HCl exposure. in sample 3, the presence of a clear band, which 
seems more prominent than that of free OVA, with chitosan:OVA nanoparticles exposed 
to trypsin suggests that OVA within nanoparticles demonstrates somewhat higher 
stability towards trypsin digestion, although the data is not quantitative. In a similar 
study SDS PAGE was used to measure protein integrity of OVA, which was destabilised 
by NaCl and the nanoparticles were placed in a 7.5 % polyacrylamide gel (Amidi et al. 
2006). The results found that the integrity of OVA was not compromised when bound to 
the chitosan nanoparticles, which is in agreement with our data. There was no evidence 
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of previously published studies that tested the stability of chitosan:OVA nanoparticles 
to HCl and trypsin, therefore a comparison with literature in this respect cannot be 
made.  
 
The stability of OVA is very important within the nanoparticle complex as the antigen 
needs to be released from the system in an intact form in order to exert the desired 
immune-inducing effect in vivo. For oral vaccine delivery, ability of the system to provide 
protection from the acidic environment of the GI tract is crucial. However, this could be 
achieved by modulating the formulation, e.g. through encapsulation of nanoparticles 
within an enteric-coated delivery system. This particular system works by coating the 
nanoparticles with the chosen enteric coating (e.g. sodium alginate), protecting the 
nanoparticle in the stomach and dissolving at an alkaline pH, e.g. the small intestine 
(Biswas et al. 2015).  
 
 
3.5 Conclusion 
 
Overall the data within this chapter demonstrated that chitosan:OVA nanoparticles 
formulated via the ionic gelation method at 1:1 mass ratio displayed optimal 
characteristics, including a diameter below 200 nm and a positive zeta potential, which 
was reduced compared to chitosan nanoparticles, in the biological solution, HBSS. This 
ratio was taken forward for cell and animal studies. Chitosan was demonstrated to 
complex with OVA at high efficiency into chitosan:OVA nanoparticles, which were 
subsequently able to release the OVA payload on exposure to the highly negatively 
charged heparin. This was clearly demonstrated by membrane 
ultrafiltration/fluorescence measurement studies. Complexation of OVA into chitosan 
nanoparticles did not compromise OVA stability (shows by SDS page). While there is 
some evidence of a degree of OVA protection to trypsin offered by chitosan 
nanoparticles, this protection is not obvious with exposure to HCl.   
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Chapter 4 
Study of Chitosan:OVA Nanoparticles in the Caco-2 In Vitro 
Intestinal Model 
 
4.1 Introduction  
 
Following the formulation and characterisation of chitosan:OVA nanoparticles in the 
previous chapter, this work investigates their effects on an intestinal cell model. Caco-2 
cells were used as a model for the intestinal barrier owing to their track record of being 
the most commonly used intestinal cell-based model. Despite their common use, there 
are several limitations associated with the Caco-2 model and these must be kept in 
mind. The model is homogenous and does not represent cell types other than epithelial 
cells, which also include Microfold cells (M cells) and mucus producing goblet cells. 
These are both important from the point of view of oral drug delivery as mucus presents 
a barrier especially to particulates. M cells are crucial in vaccine delivery owing to their 
role in antigen presenting and stimulation of mucosal immunity. Caco-2 cells typically 
take 21 days to differentiate, form tight junctions and require culture on specialist 
microporous tissue culture plates (transwell system was used in this work).  
 
This chapter outlines studies into the interaction of chitosan:OVA nanoparticles with 
Caco-2 epithelial cells. Initially, nanoparticle toxicity was tested using the MTS and LDH 
assays in order to test and make sure a non-toxic concentration was selected for future 
in vitro and in vivo studies. Thereafter, effect of nanoparticles on epithelial tight 
junctions was assessed by TEER measurements. The ability of nanoparticles to promote 
epithelial absorption of a model antigen (fluorescently labelled, FITC-OVA) was finally 
determined in permeability studys.  
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4.2 Methods 
4.2.1. MTS cell metabolic activity assay 
The MTS assay or 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-
sulfophenyl)-2H-tetrazolium reagent is reduced to a red coloured formazan product by 
the intermediate electron acceptor phenazine ethyl sulphate transferring an electron 
from NADH in the cytoplasm to MTS in the cell media. Caco-2 epithelial cells were 
seeded onto a 96 well, clear plate (cell culture treated) and were left to incubate for 24 
hours. This was for the cells to establish attachment on the bottom of the plate and 
proliferate. Nanoparticles were prepared using the described method in section 3.2.1.1. 
1 ml of the nanoparticle suspension was diluted with 9 ml of HBSS creating a 
nanoparticle suspension of 0.1 mg/ml (1:1 mass ratio). Other concentrations were also 
prepared (0.05 mg/ml, 0.025 mg/ml and 0.0125 mg/ml, all at 1:1 mass ratio). In addition 
to the nanoparticles, chitosan solution (in HBSS:MES, pH 6.0) and HBSS:MES (pH 6.0) 
were used to compare toxicity against the chitosan:OVA nanoparticles.  
 
For toxicity studies, a 10% v/v solution of triton X-100 (a surfactant known to lyse cells) 
in HBSS was prepared as a positive control and finally HBSS alone was used as a negative 
control. For toxicity studies, each concentration was applied in 6 repeats. 100 µl of each 
sample was applied to the cells into the wells, the plate placed into the incubator at 
37°C/5% CO2 for 3-hour incubation. After 3 hours, samples were removed and 100 µl of 
cell medium applied. Thereafter 20 µl of MTS reagent was applied to all the wells and 
the 96 well plate placed in an incubator at 37 °C/ 5% CO2 for 2 hours. Absorbance at 490 
nm was measured using a Tecan Infinite m200 Pro plate reader. 
 
4.2.2. Lactate Dehydrogenase Assay 
The enzyme lactate dehydrogenase is present in all cells. It is released from the 
cytoplasm when the membrane integrity is compromised. LDH interconverts lacate and 
pyruvate. Caco-2 cells were seeded onto a clear, flat-bottomed 96 well plate 48 hours 
before the assay. Cell media was aspirated from the wells and samples differing in 
concentrations (0.1, 0.05, 0.025 and 0.0125 mg/ml) and dissolved in HBSS were then 
applied to each well. 100 µl of each concentration of the sample was applied to 6 wells 
for repeats. A 10% v/v solution of triton X-100 and HBSS was prepared as a positive 
control (1 ml of triton X-100 in 9 ml of HBSS) and finally HBSS alone was also used as a 
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negative control. Chitosan:OVA nanoparticles were prepared using the method 
previously described in section 3.2.1.1. The cell media was aspirated out and replaced 
with 100 µl of the required samples and controls (n=6). Cells were incubated with 
samples at 37°C/5% CO2 for 3 hours. The LDH assay reagents were prepared according 
to manufacturer’s instructions whilst the cells were incubating. Following 3 hours 
incubation of cells with the samples, 50 µl of each sample and the controls were 
transferred to another clear flat bottomed 96 well plate. 50 µl of the reaction mixture 
prepared earlier was added to each sample and control and mixed. The plate was then 
left at room temperature for 30 minutes and covered with foil. 50 µl of stop solution 
was added to each well, mixing by gentle tapping. The absorbance of lactate 
dehydrogenase was measured at 490 nm using Tecan Infinite m200 Pro plate reader.   
 
4.2.3. TEER study  
HBSS was warmed in a water bath at 37 °C and applied to Caco-2 monolayers for 40-45 
mins for the cells to adjust to the change in environment before sample application. The 
TEER was measured (method described in section 2.2.2.) in HBSS (1.5 ml in the 
basolateral side and 0.5 ml in the apical chamber). Chitosan:OVA nanoparticles were 
prepared using the method described in section 3.2.1.1 at concentrations of 0.1 mg/ml, 
0.05 mg/ml and 0.025 mg/ml, (1:1 chitosan/OVA mass ratio). HBSS was used as a 
negative control. When the nanoparticles were ready, the HBSS was removed from the 
apical chamber and replaced with the required samples. 3 wells (n=3) were used for 
each sample for triplet repeats for validity and reliability. The TEER was measured (see 
section 2.2.2.) at time 0 and then every 30 minutes for 3 hours (30, 60, 90, 120, 150, 180 
min). A mean was taken of the samples over the given time period.   
 
This study was repeated with a 0.1 mg/ml concentration of chitosan:OVA nanoparticles, 
a solution of chitosan and ovalbumin (i.e. no TPP) at 0.1 mg/ml concentration, a 0.1 
mg/ml concentration of chitosan solution in HBSS and lastly a 0.1 mg/ml concentration 
of OVA solution in HBSS. These were used as controls or for comparison of any TEER 
effects resulting from chitosan/OVA.  
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4.2.4. Permeability study 
Caco-2 cell monolayers were cultured for 21 days. Cell monolayers with a TEER of at 
least 900 Ωcm2 were deemed suitable for cell permeability studies. TEER measurements 
were taken before permeability studies as a reassurance of the integrity of the cells. 
HBSS was warmed in a water bath to 37 °C. The cell media was aspirated out and 
replaced with HBSS;  the transwell was then placed in an incubator at 37°C/5% CO2 for 
40-45 minutes. The chitosan:OVA nanoparticles and chitosan nanoparticles were 
prepared using the methods described in section 3.2.1.1 and 3.2.1.2. Fluorescein 
isothiocyanate-labelled ovalbumin (FITC-OVA) was used for these studies instead of the 
standard non-labelled ovalbumin in order to enable quantitation by fluorescence 
measurements. Measuring fluorescence is the best method to visualise permeability 
during confocal microscopy. Nanoparticles were prepared at 1 mg/ml solution (1:1 
chitosan:FITC-OVA mass ratio) then diluted with HBSS to 0.1 mg/ml, 0.05 mg/ml, 0.025 
mg/ml and 0.0125 mg/ml.  
 
Permeability study was started by replacing HBSS with the samples at different 
concentrations (0.1 mg/ml, 0.05 mg/ml, 0.025 mg/ml and 0.0125 mg/ml). A 0 time 
sample was taken from the basolateral chamber (100 µl of sample was taken from the 
basolateral membrane chamber and placed in a 96-well black plate). A sample was then 
taken every 30 minutes for 3 hours, with replacement of the sampled basolateral 
solution with fresh HBSS. Samples were quantified by measuring the fluorescence with 
the Tecan plate reader using an excitation wavelength of 488 nm and emission 
wavelength of 520 nm.    
 
 
4.3 Results  
4.3.1 MTS Assay 
Figure 4.1 shows chitosan:OVA nanoparticle toxicity against Caco-2 cells, as determined 
via the MTS assay. The data shows concentration 0.1 mg/ml chitosan:OVA nanoparticles 
resulted in a reduction of relative cell viability to approximately 62% (negative control, 
HBSS = 100% viability and positive control, triton X-100 = 0%). As chitosan:OVA 
nanoparticle concentrations decreased, the effect on relative cell viability diminished. 
Chitosan:OVA nanoparticle concentration 0.05 mg/ml w/v displayed a reduction of 
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relative cell viability to 85% and the 0.025 and 0.0125 mg/ml were associated with a 
small reduction of relative cell viability to 94-95%. Figure 4.1 shows a concentration 
dependant correlation. 0.1 mg/ml concentration showed the lowest cell viability at 62%, 
this is because although chitosan is not toxic to cells, OVA has a slight toxicity decreasing 
cell viability. 0.1 mg/ml is also the strongest concentration and it was expected to have 
the largest decrease. However it is still over the cell viability threshold (60%). 
 
 
 
Figure 4.1 Effect of different concentrations of chitosan:OVA nanoparticles on Caco-2 relative 
viability, as determined by the MTS assay. Data shows the mean ± SD (n = 6).Cell viability  
relative to HBSS negative control. ANOVA performed, no statistical significance shown 
(P=0.413).  
 
 
 
 
 
 
0
20
40
60
80
100
120
140
0.1 mg/ml 0.05 mg/ml 0.025 mg/ml 0.0125 mg/ml
A
ve
ra
ge
 %
 (
R
e
la
ti
ve
 V
ia
b
ili
ty
)
Chapter 4         Study of Chitosan:OVA Nanoparticles in the Caco-2 In Vitro Intestinal Cell Model 
63 
 
Figure 4.2 shows a study of chitosan solution (no TPP) effect on relative cell viability, 
tested by the MTS assay. OVA was added to this study as a control. In this study, all 
tested chitosan samples showed relative cell viability higher than 100%. OVA had a 
negligible effect on cell viability.  
 
 
Figure 4.2 Effect of different chitosan solutions (no addition of TPP) and OVA (used as the 
control), on Caco-2 relative viability as determined by the MTS assay. Data shows the mean ± 
SD (n = 6). Cell viability  relative to HBSS negative control. ANOVA performed, no statistical 
significance shown (P=0.179). 
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Figure 4.3 shows the comparison of chitosan:OVA nanoparticles against chitosan 
solution at 0.1 mg/ml. This data is in agreement with figure 4.2 in that chitosan:OVA 
nanoparticles did not decrease cell viability (in fact values are very similar). Figure 4.3 
also shows that chitosan solution at 0.1 mg/ml is associated with an increase rather than 
decrease in Caco-2 cell viability. It is not known why an increase in cell viability was 
apparent in figure 4.2 and 4.3, but studies do vary (e.g. due to potential user error in 
dosage application, cell seeding density, incubation time, etc.). Although the standard 
deviation is particularly high for 0.1 mg/ml chitosan solution the results are still valid for 
a normal distribution of data.The MTS assay revealed that all of the tested samples were 
over the designated cell viability threshold (60%) for toxicity and could be taken forward 
in future experimentswithin this chapter.  
 
 
Figure 4.3 Comparison of different concentrations of chitosan:OVA nanoparticles against 0.1 
mg/ml chitosan solution in terms of Caco-2 relative viability, as determined by the MTS assay. 
Data shows the mean ± SD (n = 6). Cell viability  relative to HBSS negative control. ANOVA 
performed, no statistical significance shown  (P=0.426). 
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4.3.2 Lactate Dehydrogenase Assay 
Figure 4.4 shows the LDH assay, membrane toxicity study of chitosan:OVA 
nanoparticles. This assay measures the leakage of an intracellular enzyme, lactate 
dehydrogenase (LDH), which occurs when the cell membrane is damaged. LDH assay is 
therefore a measure of the integrity of the cell membranes, which is important to study 
for positively charged systems such as chitosan. The data below clearly shows that the 
chitosan:OVA samples are very close to the negative control, HBSS, and dramatically 
below the triton X-100 (positive control), indicating that minimal LDH was released from 
cells upon exposure to chitosan:OVA nanoparticles. The absorbance reading for triton 
X-100 was 1.029 and HBSS 0.139;  chitosan:OVA nanoparticle samples ranged between 
0.144 and 0.1612 which closely resembled values of the negative control, HBSS. Triton 
X-100 error bars are particularly large in comparison to the other samples. An 
improvement would be to normalise the cell number, SD would increase in accuracy and 
reliability. This would be an improvement for all in vitro cell studies used within this 
research.   
 
 
Figure 4.4 Effect of different concentrations of chitosan:OVA nanoparticles on LDH release. 
HBSS used as a negative control and triton X-100 as a positive control. Data shows the mean 
± SD (n = 6). ANOVA was performed, this graph is statistically significant (***=P=0.00).  
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4.3.3 TEER studies 
Figure 4.5 shows Caco-2 cell TEER measured from days 1-23 on transwell culture. The 
data shows a typical increase in TEER over time, which can be attributed to cell growth 
and tight junction formation. Towards the end of the culture and measurement period, 
the TEER plateaus. After approximately 21 days cells form a monolayer on the apical 
membrane. Caco-2 cells produce signals named contact inhibitions which tell the cells  
when there is no longer a need for an increase in resistance due to the formation of the 
monolayer.  
 
 
Figure 4.5 Caco-2 cell TEER measured over 23 days when cultured on transwell inserts. Data 
shows the mean ± SD (n = 12). 
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Figure 4.6 shows Caco-2 cell TEER with different concentrations of chitosan:OVA 
nanoparticles (0.1 mg/ml, 0.05 mg/ml, 0.025 mg/ml and 0.0125 mg/ml), as well as 0.1 
mg/ml OVA solution as a comparison. OVA solution caused a decrease in TEER to 584.33 
Ωcm2 after 60 min and continued to decrease. After 48 hours OVA solution-treated cells 
were back to original TEER values. Chitosan:OVA nanoparticle samples caused a steeper 
(faster) reduction in TEER compared to OVA solution after 30 min, although, 
interestingly, the minimum TEER values with chitosan:OVA nanoparticle samples were 
higher than those with OVA solution. With all samples, TEER values returned to the 
baseline value after 48 hours.  
 
  
 
Figure 4.6 Effect of different concentrations of chitosan:OVA nanoparticles (0.1 mg/ml, 0.05 
mg/ml, 0.025 mg/ml and 0.0125 mg/ml) and OVA solution at 0.1 mg/ml on Caco-2 monolayer 
TEER. Data shows the mean ± SD (n =3). 
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Figure 4.7 shows Caco-2 TEER values for different conditions. Chitosan:OVA 
nanoparticles were tested against chitosan solution, OVA solution and chitosan and OVA 
solution (no TPP). The values are lower than figure 4.6 although this could be due to a 
number of reasons for example each cell study will vary slightly as all cells vary after 
differentiation, the tight junctions may not have formed properly. At 24 hours the TEER 
values are  higher compared with time 0 measurement. The TEER was between 400-600 
Ωcm2 to start, the cells could have continued differentiating and forming tight junctions 
increasing the cells TEER. If this was the case the samples will have had a lower effect 
on the cells.   
 
 
 
Figure 4.7 Comparison of the effect on TEER between chitosan:OVA nanoparticles, chitosan 
solution, OVA solution and chitosan and OVA solution (no TPP). Data shows the mean ± SD (n 
= 3).  
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4.3.4 Permeability studies 
Permeability studies are calculated using the equation described earlier in chapter 2 
section 2.2.6. Figure 4.8 shows apical-to-basolateral permeation of FITC-OVA, following 
application of chitosan:FITC-OVA nanoparticles to Caco-2 monolayers at different 
concentrations. Note that FITC-OVA was quantified in these studies through 
fluorescence measurement and it is not possible to state whether FITC-OVA crossed the 
cells complexed in chitosan nanoparticles or whether it was released en route. The 
concentration which showed the highest permeation was 0.1 mg/ml, i.e. the highest 
applied concentration of chitosan:OVA nanoparticles. This concentration had the lowest 
cell viability in figures 4.1 (62%) and 4.3 (137%). Apart from the lowest concentration, 
other samples displayed a concentration-dependent effect with permeability being 
proportional to applied chitosan:OVA nanoparticle concentration. There is no clear 
reason why concentration 0.0125 mg/ml increased however it could be due to 
background noise or seeding density errors.  
 
 
Figure 4.8 FITC-OVA permeability following application of chitosan:FITC-OVA nanoparticles at 
different concentrations. Data shows the mean ± SD (n = 3). ANOVA test was performed, no 
statistical significance shown  (P=0.303). 
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Figure 4.9 shows another permeability experiment, comparing FITC-OVA permeability 
following the application of chitosan:OVA nanoparticles at a concentration of 0.1 mg/ml 
(1:1 mass ratio) and 0.1 mg/ml of FITC-OVA solution. The graph shows that FITC-OVA 
permeability across Caco-2 monolayers was significantly higher than OVA in solution 
with all chitosan:OVA nanoparticle concentrations.  
 
Figure 4.9 FITC-OVA permeability following application of chitosan:FITC-OVA nanoparticles at 
0.1 mg/ml and comparison with OVA in solution, applied at 0.1 mg/ml. ** = P=0.0036. 
 
4.3.5 Confocal imaging 
 
Following the permeability study with chitosan:FITC-OVA nanoparticles at 0.1 mg/ml, 
cells were imaged using confocal microscopy in order to ascertain information on the 
cell uptake of the nanoparticles.  
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Figure 4.10 shows the presence of fluorescence due to FITC-OVA within the cells. 
However, with this information available, it is not clear on whether FITC-OVA remains 
complexed with chitosan in the cell interior or if it is released before entering the cells. 
Unfortunately there is no negative cntrol for comparison.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Magnified confocal imaging following the application of chitosan:FITC- OVA 
nanoparticles on Caco-2 cells, applied at 0.1 mg/ml There is no negative control.  
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Figure 4.11 shows the cell depth of a section of Caco-2 monolayers following application 
of 0.1 mg/ml chitosan:FITC-OVA nanoparticles. This micrograph demonstrates the 
presence of fluorescence, most likely attributed to chitosan:FITC-OVA nanoparticles, in 
cells. Figure 4.11 shows the uptake of chitosan:FITC-OVA nanoparticles in Caco-2 
epithelial cells. The figure shows the chitosan:FITC-OVA nanoparticles passing through 
the cells, concluding the transcellular pathway is most likely used.   
 
Figure 4.11 Confocal imaging of cell depth when treated with 0.1 mg/ml chitosan:FITC-OVA 
nanoparticles. Chitosan:FITC-OVA nanoparticles stained green and Caco-2 cells stained blue 
with DAPI.   
 
 
4.5 Discussion 
The aim of the work in this chapter was to test the toxicity and antigen (OVA, used as a 
model antigen) delivery potential of chitosan nanoparticles. The toxicity was tested 
through the MTS assay to test cell viability and LDH assay to test the effect the 
chitosan:OVA nanoparticles had on the integrity of the cell membranes. Effect on 
epithelial tight junctions was assessed via TEER studies and permeability studies were 
employed to determine whether OVA translocates across Caco-2 monolayers.  
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Figure 4.3 shows that chitosan:OVA nanoparticles did not reduce Caco-2 cell viability at 
tested concentrations. In a similar study chitosan nanoparticles via ionic gelation, used 
the MTS assay to show a concentration-dependent effect on Caco-2 cells, with 0.025 
mg/ml concentration showing the greatest reduction in cell viability. Chitosan solution 
of comparable concentration showed a similar effect on Caco-2 cells (Vllasaliu et al. 
2010). It is interesting to note that  application of chitosan solution to Caco-2 cells at 0.1 
mg/ml w/v resulted in a dramatic reduction in cell viability, to 26% (Vllasaliu et al. 2010), 
whereas in the present work chitosan:OVA nanoparticles at the same concentration of 
chitosan did not decrease cell viability. This may be related to the presence of OVA in 
the system, possibly due to a reduction in the positive surface charge of nanoparticles, 
as demonstrated by zeta potential measurements (Chapter 3).   
 
Lactate dehydrogenase (LDH) is a soluble cytoplasmic enzyme which is released when 
the cells are lysed or damaged; this is used as a measurement of membrane toxicity to 
cells. LDH catalyses the following reaction; NADH+ pyruvate ↔ NAD+ Lactate (Chen et 
al. 2015). NADH is reduced to β- nicotinamide adenine dinucleotide when pyruvate is 
oxidised to lactate, a tetrazolium salt is then produced into a coloured formazan product 
using synthesised NADH in the presence of an electron acceptor. The formazan product 
is then measured by spectroscopy at 490 nm (Chan et al. 2013).  
 
Chitosan:OVA nanoparticles at all tested concentrations did not significantly increase 
LDH release and displayed values similar to HBSS (negative control). A similar study 
demonstrated that there was no cytotoxicity observed in the chitosan nanoparticles, 
compared to metal or metal oxides encapsulated in nanoparticles, which is known to be 
cytotoxic to cells (Yang et al. 2015). Another study demonstrated an LDH assay 
conducted with chitosan nanoparticles formulated by ionic gelation, although this was 
on airway Calu-3 cells. This study described a concentration-dependent increase in LDH 
release and Calu-3 cells were significantly more sensitive to chitosan application 
compared to the present study with chitosan:OVA system in Caco-2 cells (Vllasaliu et al. 
2010).        
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Transepithelial electrical resistance (TEER) was studied to establish if the nanoparticles 
caused tight junction modulation. TEER is a strong indicator of the integrity of the 
epithelial barriers, including tight junction function and modulation.  
 
TEER reduction was observed in this work, although the same observation was also 
apparent for OVA solution at concentration equivalent to that present in nanoparticles 
(0.1 mg/ml). It is interesting to note that the pattern of TEER reduction was different in 
chitosan:OVA nanoparticles to OVA solution (control), with the latter associated with a 
delayed effect (maximum TEER reduction at 120 min compared to 30 min with 
chitosan:OVA nanoparticles).All the concentrations of chitosan:OVA nanoparticle 
samples at the 24 hour and 48 hour measurement, the TEER always returned back to its 
original value suggesting reversibility. This is another indication of no toxicity exerted by 
nanoparticles to Caco-2 cells. This suggests that the chitosan:OVA nanoparticles do not 
cause irreversible damage to Caco-2 cells, but is not clear whether a tight junction 
modulating effect is exerted. 
 
TEER reversibility with chitosan nanoparticles has been reported previously, including in 
a study with chitosan nanoparticles based on a chitosan oligosaccharide formed via ionic 
gelation (Ye et al. 2013 and Vllasaliu et al. 2010). 
  
A clear ability to decrease TEER has been previously reported with chitosan 
nanoparticles. For example, in a similar study chitosan nanoparticles were prepared 
using ionotropic gelation through the method of spinning disc processing technology. 
Test samples were also formed in HBSS and applied to Caco-2 cells. HBSS was used as a 
control and baseline as within this research. Chitosan in solution was compared against 
chitosan nanoparticles. As the chitosan nanoparticles increased in concentration, cells 
decreased in TEER over a course of 3 hours to 86%, 32% and 24% above the original 
baseline value (Loh et al. 2012). A similar effect is shown in another study using chitosan 
chloride nanoparticles prepared by ionic gelation, with nanoparticles at 0.0125 mg/ml 
being able to cause a dramatic reduction in TEER in Caco-2 cells, to <20% of the baseline 
value (Vllasaliu et al. 2010).   
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It could be hypothesised that the reason why the chitosan:OVA nanoparticles in this 
work did not induce a dramatic reduction in Caco-2 monolayer TEER relates to the 
surface charge reduction of the systems, similarly to the toxicity effect. It was 
hypothesised in a similar study the reduced charge density at the surface of the 
nanoparticles, compared to the soluble form of chitosan, was responsible for a much 
lower effect on chitosan nanoparticles compared to solution, decreasing the TEER 
(Sadeghi et al. 2008). Similarly, in our chitosan:OVA nanosystems the reduction of 
positive surface charge and shielding of amine chitosan groups by OVA may be 
responsible for the decreased effect on tight junctions, hence cell monolayer TEER, 
compared to previous observations with chitosan only nanoparticles.  
 
Permeability studies were performed to determine OVA as a model antigen complexed 
within chitosan nanoparticles moved across the Caco-2 monolayers. This was studied 
over a 3-hour period. Data demonstrates OVA permeability (apparent permeability 
coefficient, Papp) is higher when applied in chitosan:OVA form compared to equivalent 
dose of OVA in solution. It must be noted that due to the nature of the experimental 
procedure, whereby fluorescently labelled OVA was quantified, it is not possible to 
establish whether chitosan:OVA nanoparticles permeated the cell monolayers or if OVA 
dissociated from the nanoparticles, before or during the transit process. However, 
confocal microscopy data (Figures 4.10 and 4.11) shows chitosan:OVA nanoparticles are 
taken up by Caco-2 cells (within polarised monolayer culture).  
 
The polymer chitosan enhanced nanoparticle uptake from electrostatic interactions 
occuring when the positive amine groups on chitosan bound to the negatively charged 
intergrins on the epithelial cell surface. As stated above it is not known whether FITC-
OVA was released after dissociation from nanoparticles or whether the chitosan:FITC-
OVA nanoparticles passed through the cells. Throughout the permeability studies in 
different concentrations tested, the concentration of FITC-OVA was kept the same. 
Chitosan concentration varied it was this variable which showed the relationship 
between permeability and the concentration used. The higher the concentration (0.1 
mg/ml) the increase in permability of FITC-OVA in Caco-2 cells. A way to test and 
improve the permability studies would be to fluorescently label chitosan. This would 
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measure the permeability of chitosan and demonstrate if FITC-OVA dissociated with 
chitosan before passing through the Caco-2 cells.  
 
In similar research chitosan nanoparticles were prepared via ionic gelation method using 
tripolyphosphate. Permeability studies using a Caco-2 cell line took place using FD4 as a 
model macromolecule. The transwell was tested in different conditions: FD4 alone, 
chitosan nanoparticles and hydrocaffeic acid chitosan nanoparticles with FD4. This study 
found that the FD4 permeability was increased with the addition of nanoparticles 
compared to when applied alone in solution (Soliman et al. 2014). Prior to this, a study 
also used FD4 and FD10 as model drugs and clearly demonstrated that chitosan 
nanoparticles markedly enhanced the permeability of FD4 and FD10, by 7.6 fold and 6.5 
fold, respectively. However, this study also showed that chitosan nanoparticles 
dramatically reduced cell monolayer TEER, suggesting a tight junction modulating effect 
(Vllasaliu et al. 2010). Interestingly, work in this thesis also shows an increase in payload 
(OVA) permeability across Caco-2 monolayers, which is notable considering the higher 
molecular weight of OVA compared to FD4 or FD10, but without a clear demonstration 
of a tight junction effect (TEER).  
   
Permeability data in this work showed FITC-OVA within chitosan:FITC-OVA nanoparticles 
crossed Caco-2 monolayers more efficiently than FITC-OVA alone in solution, with a 5-
fold enhancement in permeability. The mechanism responsible for this increased apical-
to-basolateral permeability of FITC-OVA is more likely to relate to nanoparticle 
trancellular uptake by Caco-2 cells rather than the effect on the paracellular route. 
Chitosan:OVA’s potential to open up Caco-2 tight junctions and allowing the OVA to 
diffuse through the paracellular route is not clear due to the effect of the nanoparticle 
system on cell monolayer TEER not being notably lower than OVA solution.A 
transcellular rather than paracellular effect is more likely, and is also confirmed by 
confocal microscopy, which shows fluorescence presence in cells (FITC-OVA in 
chitosan:FITC-OVA nanoparticles). The relatively small size of chitosan:OVA 
nanoparticles prepared in this work (compared to previous studies reporting chitosan 
nanoparticle preparation with the ionic gelation method) is likely to facilitate the cell 
uptake of nanoparticles.  
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4.6 Conclusion 
 
Overall, the research within this chapter tested various biological effects of 
chitosan:OVA nanoparticles, including cytotoxicity (MTS and LDH assay), effect on tight 
junctions (TEER) and FITC:OVA permeability in Caco-2 monolayers. It was found that all  
chitosan:OVA nanoparticle concentrations testedwere not toxic to the Caco-2 cells in 
MTS assay or LDH assay and were over the cell viability threshold (60%). It was also 
found that TEER decrease with chitosan:OVA nanoparticles is not clear as the effect does 
not go beyond that of OVA solution alone. Permeability studies showed FITC-OVA 
permeability is notably facilitated following nanoparticle application compared to OVA 
solution. Lastly confocal imaging showed fluorescence presence, assumed to be due to 
chitosan:FITC-OVA nanoparticles in the interior of Caco-2 cells. Together, the data 
suggests that chitosan:OVA nanoparticles are not toxic towards Caco-2 cells and are able 
to improve antigen delivery, most likely through the transcellular route.  
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Chapter 5 
In Vivo Study of Chitosan:OVA Nanoparticles for Immune 
Response 
 
5.1 Introduction 
 
This chapter details an investigation of whether chitosan:OVA nanoparticles are able to 
induce a positive immune response in mice following  gastrointestinal administration (to 
stimulate oral delivery). To measure the immune response, IgG and IgA were measured 
and IgG1 and IgG2A subclasses were analysed, as well as total IgG using an indirect ELISA. 
This was carried out at the National Institute for Biological Standards and Control 
(NIBSC) by myself. The IgG subclasses provide evidence in antibody responses of CD4 
positive T cell functions in acquiring immunity. IgG1 is the most abundant Ig in the IgG 
subclass (50%). Th1 and Th2 response reflects the IgG1 response (Nakayama et al. 2012). 
IgG2a is a marker for Th1 and Th2 lymphocytes and is the second most abundant 
antibody in the human immune system. IgG2a responses are usually not as high as IgG1. 
However, as it is a marker for Th1 and Th2 activation it is still important to measure 
(Mountford et al. 1996). IgA measurement in this study was important as this 
immunoglobulin inhabits the mucosa and can give an indication of mucosal response. 
IgA response has been shown to play an important role in immunity; it activates the 
alternative pathway in the complement system which in turn helps to prevent serious 
infections (Roos et al. 2001).   
 
Although a number of nanosystems have been tested previously for mucosal vaccine 
delivery, one of the most extensively researched nanoparticle systems are those 
formulated from chitosan. For example, chitosan nanoparticles have shown to produce 
a response when cholera toxin and OVA (used as an adjuvant) have been used (Huang 
et al. 2008), as well as hepatitis B surface antigen and meningococcal C oligosaccharides 
(Slütter and Jiskoot. 2010). However, due to the great diversity in chitosan systems, 
including the type of chitosan molecule used (e.g. specific salt form and molecular 
weight), as well as formulation method, this study focused on a specific chitosan 
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(ultrapure chitosan chloride) and formulation method (ionic gelation) which had 
previously shown significant potential for enhancing mucosal drug absorption (Casettari 
et al. 2012, Vllasaliu et al. 2012 and Casettari et al. 2012).   
 
Chapters 3 and 4 showed that chitosan nanoparticles fabricated in this work capable of 
complexing with OVA, display a good overall toxicity profile and enhance OVA 
permeability across Caco-2 monolayers. Following this demonstration, this chapter 
tested the performance of the system in vivo. This is important as the in vitro outcome 
of many drug formulation systems is often not reproduced in vivo. In this case transwell 
systems designed to deliver the therapeutic payload across the mucosal surfaces, the 
epithelial models may not faithfully represent the more complex mucosal surfaces, 
which consists of multiple cell types and have mucus presence. The immune response 
to chitosan:OVA nanoparticles in animal studies was measured by performing indirect 
ELISAs on mouse sera, looking at individual immunoglobulins; IgG, IgG1, IgG2A and IgA 
carried out at NIBSC by myself. This was to establish which part of the immune system 
was involved in any positive response that may take place. 
 
5.2 Methods 
5.2.1 Preparation of chitosan:OVA nanoparticles for in vivo studies  
Only one concentration of nanoparticles was prepared, namely 1 mg/ml (1:1 
chitosan:OVA mass ratio). This concentration has shown the opitmal size, charge, 
toxicity and permeation following previous in vitro studies. 4 mg chitosan was dissolved 
in 2 ml of MES/HBSS solution (pH 6.0). In a separate scintillation vial, 4 mg endotoxin-
free OVA was dissolved in 2 ml MES/HBSS solution. 1.5 ml of chitosan solution and 1.5 
ml of OVA solution (both at 2 mg/ml) were then mixed in a scintillation vial (a total 
volume of 3 ml of nanoparticles was needed overall), with the overall final concentration 
of both chitosan and OVA at 1 mg/ml. TPP was added to this solution in a dropwise 
manner using a needle (with stirring) to produce the nanoparticles. These were then 
sent to the National Institute for Biological Standards and Control (NIBSC) for use in in 
vivo studies.  
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5.2.2 Oral immunisation of BALB/c mice 
This was performed by Dr Donna Bryan at  NIBSC. (Ethical approval was obtained, 2015). 
At no point were the nanoparticles sterilised before immunisation. 25 BALB/c mice were 
immunised with chitosan:OVA nanoparticles with or without 15 µg cholera toxin (Vibrio 
cholerae), as well as OVA alone with or without 15 µg cholera toxin (added as a second 
adjuvant to further enhance the mucosal response). This was done by oral gavage. A 
subcutaneous group was used as a positive control with a lower dose of OVA. Mice were 
pre-bled at day -1 and immunised at days 0, 7, 14 and 28. Each group of mice were 
assigned a sample. A tail bleed was taken at day 20 and terminal bleed was performed 
at day 28. Serum was prepared and stored at -80 °C. Faecal samples were collected and 
placed into an Eppendorf containing a protein degradation inhibition solution at day 28. 
Intestinal washes were carried out at day 28. This was performed by removing the small 
intestine and washing it with a protein degradation inhibition solution, the supernatant 
was stored at -80 °C.  
5.2.3. Quantitation of IgG, IgG1, IgG2a and IgA by indirect ELISA following oral 
immunisation of mice 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 A diagram of an indirect ELISA. 
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95 ml of carbonate buffer was prepared (see section 2.2.3.5) and then placed in a duran 
bottle to which 950 µl of endograde OVA (endotoxin free) was added and mixed. This 
particular type of OVA was chosen based on previous research that it does not cause 
any immune response due to toxins. Using a multi pipette, 100 µl of the mixture was 
placed into 9 96 well plates. The plates were then incubated at 37 °C for 90 minutes and 
then at 4 °C overnight.  
 
After the plates were taken out of the fridge, the ovalbumin mixture was aspirated out. 
The plates were placed in the plate washer. The 9 plates were washed with the prepared 
wash buffer (see section 2.2.3.3.). The plates were blocked with the prepared assay 
diluent (Section 2.2.3.4.); 100 µl was applied per well to all plates and placed in the 
incubator for 30 minutes at 37 °C. This is an important step in the ELISA protocol. 
Blocking the wells with assay diluent ensures a reduction in background noise, the 
prevention of non-specific binding and stabilisation of proteins absorbed to the plate 
already (OVA). Meanwhile the samples were prepared. 490 µl of assay diluent was 
placed in an Eppendorf, followed by 10 µl of collected mouse sera. 5 sample groups with 
5 mice in each group were used, as depicted in table 5.1.  
Group Sample 
1 200µl  Ovalbumin mixed with sodium bicarbonate.  
2 200µl  Ovalbumin mixed with cholera toxin and sodium bicarbonate. 
 
3 200µl Chitosan:OVA nanoparticles in PBS. 
4 200µl Chitosan:OVA nanoparticles with cholera toxin. 
5 200µl Ovalbumin alone mixed with PBS administered subcutaneously 
(control). 
Table 5.1 Mouse sera samples used in indirect ELISA's   
 
The positive control was reference sera (dilution 1:50) placed in row 1 and 2, a blank of 
assay diluent was also used in column 12.  
 
Samples were applied to the plates and incubated for 90 minutes at room temperature 
(approximately 22 °C). The plates were washed using the same process as before (see 
above). The secondary antibody was prepared. 95 ml of assay diluent mixed with 31.5 
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µl of goat anti-mouse antibody in a duran bottle. 100 µl was applied to every well in all 
9 plates and left at room temperature for 90 minutes. The o-Phenylenediamine 
dihydrochloride (OPD) peroxidase substrate (horseradish peroxidase enzyme) was 
prepared. 50 ml of dH2O was applied to two plastic containers; 5 gold wrapped tablets 
were added to one container and 5 silver wrapped tablets were added to another 
container. The containers were wrapped in foil and the tablets dissolved by continuous 
stirring. Once dissolved, the tablets wrapped in silver solution was poured into the 
container containing the gold wrapped tablets. Once the plates were ready, they were 
washed using the plate washer. 100 µl of the OPD substrate was applied to all the wells 
in the plates to label the second antibody (goat anti-mouse antibody). These were 
placed in a dark cupboard for 20 minutes. The reaction was stopped with hydrochloric 
acid and 50 µl applied to all the wells in all 9 plates. The plates were read with the plate 
reader at 492 nm. 
 
The role of each component of an indirect ELISA:  
 Endograde free OVA- antigen used. 
 Mouse sera samples- used to bind to the chosen antigen 
 Goat anti- mouse antibody- used to bind to primary antibody 
 OPD peroxidase substrate- used to label the secondary antibody to read optical 
density. 
 
 
5.3 Results 
Total IgG, IgG1, IgG2A and IgA were tested throughout the in vivo studies. This was in 
order to determine the mechanisms of the immune response. There were 5 groups with 
5 mice in each group for repeats.  
 
Figure 5.2 shows the response elicited with ovalbumin mixed with bicarbonate. This was 
non-existent to minimal. This sample was not expected to show a response, but was 
used as a baseline. It does not match the same pattern as the positive control. The 
standard deviation was 0.024 and geomean 0.237 indicating a poor response. The value 
of the SD is to define the distribution of the blank samples of different mice, the 
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geometric mean determines the central tendancy of the product of the blank samples 
of different mice. This determines the 'cut off' for antibody titres on the ELISA and figure 
5.2   
 
 
Figure 5.2 IgG1 response of group 1: ovalbumin mixed with bicarbonate. Positive control is 
standard reference sera. 
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Figure 5.3 shows the immune response to the combination of ovalbumin and cholera 
toxin. A clear response is apparent with two mice, with the highest response from mouse 
2-2 at 0.824. These show a similar pattern to the positive control but with a  lower 
response. This sample was another baseline and could be compared with chitosan:OVA 
nanoparticles to determine whether the system showed an increased response 
compared to the combination of ovalbumin with cholera toxin. The standard deviation 
was 0.138 and geomean 0.277 (slightly higher than for ovalbumin mixed with 
bicarbonate, figure 5.2). 
 
 
 
Figure 5.3 IgG1 response for group 2: ovalbumin with cholera toxin. Positive control is standard 
reference sera. 
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Figure 5.4 shows IgG1 response to chitosan:OVA nanoparticles (group 3). The graph 
suggests the absence of an IgG1 response in mice following oral immunisation with 
chitosan:OVA nanoparticles.  
 
 
 
 
Figure 5.4 IgG1 response to chitosan:OVA nanoparticles. Positive control is standard reference 
sera.  
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IgG1 response to chitosan:OVA nanoparticles with cholera toxin is shown in figure 5.5. 
Cholera toxin was added to nanoparticles as an extra adjuvant. The data does not follow 
a clear pattern. None of the samples follow the positive control pattern. Standard 
deviation was 0.02 and the graph had a geomean of 0.275. This was similar to figure 5.3.  
 
 
  
Figure 5.5 IgG1 response in group 4: chitosan:OVA nanoparticles with cholera toxin. Positive 
control is standard reference sera. 
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Figure 5.6 shows subcutaneous administration control group. The samples gave rise to 
a mixed IgG1 response, with 4 mice showing a higher response than the positive control. 
The standard deviation was 0.023. A geomean of 0.302 indicates an increase compared 
to figures 5.2- 5.5above.  
 
 
 
 
Figure 5.6 IgG1 response of group 5: ovalbumin mixed with PBS, administered subcutaneously. 
Positive control is standard reference sera. Negative control is a blank.  
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Figure 5.7 shows IgG2a response with chitosan:OVA nanoparticles. There appears to be 
no particular pattern in this instance, however most samples are above the positive 
control line. The standard deviation is 0.026 and geomean 0.468, the latter being 
notably higher than any previous figures.  
 
 
 
Figure 5.7 shows IgG2a response in group 3: chitosan:OVA nanoparticles. Positive control is 
standard reference sera. 
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Figure 5.8 shows an IgG2a response to chitosan/OVA nanoparticles with the addition of 
cholera toxin at a 1:50 dilution. There is no trend, with sample values above the positive 
control and constant decrease and increase in response value. There is no clear 
indication were the antibody titres end. The standard deviation is higher at 0.063 and 
geomean is 0.473. There is one anomaly where sample 3 peaks at 1:3200 dilution at 
1.091. This could be down to background noise or the plate washer needles being 
blocked with a previous sample causing contamination in this particular study.   
 
 
 
 
 Figure 5.8 shows IgG2a response in group 4: chitosan:OVA nanoparticles with cholera toxin. 
Positive control is standard reference sera. 
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Figure 5.9 shows total IgG response to chitosan:OVA nanoparticles at a 1:50 dilution. 
The figure shows a slight increase in response to the chitosan:OVA nanoparticles. The 
highest value at 1:50 is 0.278, although the positive control was 2.106. The standard 
deviation was 0.013 and geomean 0.221. 
 
 
 
 
Figure 5.9 total IgG response to 1:50 dilution group 3: chitosan:OVA nanoparticles. Positive 
control is standard reference sera. 
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Figure 5.10 reveals total IgG response in chitosan:OVA nanoparticles with cholera toxin 
at a 1:50 dilution. A similar trend to figure 5.9 is apparent. There is a positive trend on 
the graph, the highest value is 0.593 showing the addition of cholera toxin increases the 
immune response. The standard deviation was 0.006 and geomean is 0.230.  
 
 
 
 
Figure 5.10 total IgG response in group 4: chitosan:OVA nanoparticles with cholera toxin. 
Positive control is standard reference sera. 
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As total IgG response with chitosan:OVA nanoparticles with cholera toxin was apparent 
starting with a 1:50 dilution, a 1:10 dilution was tested as well. Figure 5.11 shows a 
higher response compared to previous scenarios. The highest total IgG response value 
is 1.222, there is a trend to this graph with all the samples following the same pattern 
as the positive control. The standard deviation is 0.003 which shows a very narrow 
distribution of data and the geomean is 0.168.  
 
 
 
 
Figure 5.11 total IgG response in chitosan:OVA nanoparticles (group 3), starting at 1:10 
dilution. Positive control is standard reference sera. 
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Figure 5.12 shows immune response to the chitosan:OVA nanoparticles with cholera 
toxin and demonstrates a trend similar to control. However, figure 5.11 shows a higher 
response than figure 5.12. Figure 5.12 shows a mean of 0.077 whilst figure 5.11 shows 
a mean of 0.084. The geomean is 0.154 which is again lower than figure 5.11. We can 
conclude from these two figures that the samples with the addition of cholera toxin 
produces a lower immune response than the samples without, which is not what was 
observed in previous experiments. 
 
 
 
 
Figure 5.12 total IgG response to group 4: chitosan:OVA nanoparticles with cholera toxin, 
starting at 1:10 dilution. Positive control is standard reference sera. 
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Figure 5.13 shows IgA response to intestinal washes of BALB/c mice treated with 
chitosan:OVA nanoparticles. Response is apparent at higher dilutions. All of the samples 
are above the positive control. The standard deviation is 0.038 and geomean is high at 
0.675. The reading for the blank was high and could have been background noise. As it 
was also a higher dilution (1:2) this could have contributed to it.   
 
 
 
 
Figure 5.13 IgA response in intestinal washes (1:2 dilution) of group 3: chitosan:OVA 
nanoparticles. Positive control is standard reference sera. 
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Figure 5.14 shows IgA intestinal washes response to chitosan:OVA nanoparticles with 
cholera toxin. A greater immune response at dilution 1:2 is seen but steeply decreases. 
The values remain low throughout the rest of the graph. The standard deviation is 0.049 
and geomean 0.496 is relatively high. This again could be down to the stronger dilution 
used. 
 
 
 
 
Figure 5.14 response to IgA intestinal washes 1:2 dilution group 4: chitosan:OVA nanoparticles 
with cholera toxin. Positive control is standard reference sera. 
 
Figure and condition tested Ig response 
5.2 IgG1-ovalbumin mixed with 
bicarbonate.  
No IgG1 response was detected. 
5.3 IgG1-ovalbumin mixed with cholera 
toxin and sodium bicarbonate 
A limited IgG1 response (0.82) was 
detected. 
5.4 IgG1-chitosan:OVA nanoparticles in 
PBS. 
No IgG1 response was detected 
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5.5 IgG1-chitosan:OVA nanoparticles with 
cholera toxin. 
No clear IgG1 response shown. 
5.6 IgG1-ovalbumin alone mixed with PBS 
administered subcutaneously.   
A clear IgG1 response was shown by 4 
mice for the positive control.  
5.7 IgG2a-chitosan:OVA nanoparticles in 
PBS. 
There was no clear IgG2a response 
shown. 
5.8 IgG2a-chitosan:OVA nanoparticles 
with cholera toxin. 
There was no response or trend to IgG2a. 
5.9 total IgG-chitosan:OVA nanoparticles 
in PBS. 
There was a limited response shown. 
5.10 total IgG-chitosan:OVA 
nanoparticles with cholera toxin. 
There was a small response shown (0.59).  
 
5.11 total IgG (1:10 dilution) 
chitosan:OVA nanoparticles in PBS. 
There was a large response 
demonstrated (1.22)  
5.12 total IgG (1:10 dilution) 
chitosan:OVA nanoparticles with cholera 
toxin. 
There was a large response (1.10). 
5.13 IgA-chitosan:OVA nanoparticles in 
PBS. 
There was no clear response. 
5.14 IgA-chitosan:OVA nanoparticles with 
cholera toxin. 
There was no response. 
Table 5.2 Summary of Ig responses via different conditions tested. 
 
In summary there were unexpected and surprising results. IgG1 produced no results, 
there were also no clear IgG2a results. Total IgG (1:50 dilution) produced a small 
response, so a stronger dilution was produced. Total Ig (1:10) produced a strong and 
robust response to the chitosan nanoparticles clearly matching the pattern of the 
positive control sera used. The response was stronger without the cholera toxin which 
was unexpected. IgA did not produce any valid response.  
 
5.4 Discussion 
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Looking at the data in this chapter, it is apparent that chitosan:OVA nanoparticles, which 
successfully enhanced transepithelial permeability of OVA in the Caco-2 intestinal model 
(chapter 4). The chitosan:OVA nanoparticles did not produce an IgG1 or IgG2a response 
following oral immunisation.  
 
A study used BALB/b mice during immunisation studies with alginate coated chitosan 
nanoparticles encapsulating measles antigen, prepared via ionotropic gelation using 
tripolyphosphate. The alginate protects the chitosan:measle nanoparticles from 
degradation during the immunisation studies. The mice were immunised via the oral 
route; a subcutaneous vaccination group was also carried out to serve as a positive 
control. The mice sera were tested using ELISA for IgG antibody. Intestinal washes were 
also carried out - this was to extract immunoglobulins from mucin in the small intestine. 
The study found the presence of measles specific IgG and IgA in the serum tested, the 
subsequent antibody titres through a DBS (dried blood spot) assay concluded as the 
immunisations increased, the antibody titres increased. It was also found that the IgG 
levels were higher for low molecular weight chitosan than higher molecular weight 
chitosan. These responses increased over a period of 14 days after plateauing. However, 
the subcutaneous group demonstrated the highest antibody titre (used as a positive 
control). From the intestinal lavages there was an increase in IgA secretion in low 
molecular weight alginate coated chitosan nanoparticles. There was a significant 
correlation with the amount of IgA induced and the molecular weight of the chitosan. 
The lower the molecular weight the more IgA was produced. The subcutaneous group 
did not produce any IgA response, even with the addition of booster immunisations 
(Biswas et al. 2015). 
 
The above study employed alginate:chitosan nanoparticles and measles as an antigen 
and mice used were immunised via the oral route, similarly to our work. The difference 
in observations between the above study and our work is probably related to the 
antigen. OVA used in our work may not elicit as strong an immune response as the 
measles antigen. However, the discrepancy in observations could also be related to the 
different formulation (chitosan:OVA versus alginate:chitosan).   
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Chitosan:OVA:diphtheria toxoid nanoparticles were prepared in a similar study. The 
chitosan:OVA:diphtheria loaded nanoparticles were subsequently up taken by Peyers 
patches (which are the target for oral vaccinations) after the chitosan:OVA:diphtheria  
nanoparticles were intragastrically fed to mice (Lubben et al. 2001). For chitosan 
microparticles to be up taken by Peyers patches the size needs to be <10 µm in diameter 
(Islam et al. 2012). The uptake was demonstrated via confocal laser scanning 
microscopy. The chitosan:OVA:diphtheria nanoparticles easily associated with the 
negatively charged DNA. It has shown promising results via nasal delivery producing 
mucosal responses, which is why it is a promising candidate for oral vaccine delivery 
(Lubben et al. 2001). 
 
Similar research used chitosan:OVA nanoparticles administered nasally, producing 
significant mucosal responses. Following administration of chitosan:OVA nanoparticles, 
mice exhibited a significant increase in IgG antibodies and a long lasting immune 
response, similarly to intramuscular administration (Li et al. 2001). IgA antibody 
response was also significantly increased compared to that of a soluble antigen. 
Diphtheria toxoid was used as well as OVA in the chitosan nanoparticles in the previous 
study. This produced an increased uptake in Peyers patches in the ileum (Lubben et al. 
2001). The difference between our work and the above study is related to the antigen. 
The OVA used did not produce a strong immune response compared to diphtheria 
toxoid used (Lubben et al. 2001). The rest of the study was conducted in a similar 
method to our research. Different results were exhibited however the chitosan:OVA 
nanoparticles were administered nasally, not orally (Li et al. 2001).   
 
Comparable research studied the immune response from synthesised chitosan 
derivatives delivered orally using OVA as an antigen (Suksamran et al. 2012). 
Quaternisation of chitosan can increase and preserve its solubility and positive charge 
within a neutral pH (Chen et al. 2013). One of chitosans qualities is its ability to cause an 
immune response without any off target immunogenicity  (Islam et al. 2012). Six groups 
of six female BALB/c mice were immunised on days 0 and 14, each group with a different 
sample. A positive subcutaneous group of 100 µg OVA with 200 ml of Al(OH)3 was used, 
and a negative control of 500 µg OVA in PBS administered orally. The rest of the samples 
used in the groups were chitosan derivatives with different aromatic moieties. Tail 
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bleeds were performed on day 0 and after anaesthetising the mice on day 21 a cardiac 
puncture was performed to collect blood samples. Serum samples obtained from the 
tail bleeds were kept separate (Suksamran et al. 2012). ELISAs were performed to 
determine the IgG OVA specific antibody response (Slütter et al. 2009). As expected the 
IgG titres for day 0 were very low, after the second immunisation the IgG levels 
significantly increased. The samples using OVA in chitosan derivative solutions induced 
a higher immune response than OVA in PBS (negative control); although the immune 
response was lower than OVA with Al(OH)3 (positive control). The differences between 
the immune responses of the chitosan derivatives varied. The derivative sample with 
the highest immune response was TM65CM50, compared to TM65, TM56Bz42 and 
TM53Py40. All concentrations used were 0.1 mg/ml (Suksamran et al. 2012).       
 
Compared to the above study, our research employed a similar method. BALB/c mice 
were used, although more immunisations were applied (Suksamran et al. 2012). Serum 
samples were collected, there were no faecal samples collected or intestinal gavages 
performed. The difference between the above study and our research is different 
derivatives of chitosan were tested (Suksamran et al. 2012). In comparison, our work 
used one chitosan formulation (chitosan:OVA nanoparticles). An improvement to our 
research would be comparison of different chitosan derivatives, but our study was based 
on previously demonstrated potential (clear absorption enhancing effects) of ultrapure 
chitosan chloride.  
 
Another study demonstrated, chitosan microparticles were prepared and three 
vaccination studies were carried out. The first vaccination study consisted of three 
groups of five mice vaccinated intragastrically with the following solutions: 
chitosan:diphtheria toxin microparticles, diphtheria toxin in PBS and chitosan 
microparticles alone. A second study was carried out to determine a dose dependant 
relationship. The last vaccination study to take place used two groups of six mice, one 
group received 40 fl diphtheria toxin associated chitosan microparticles and the second 
group received 40 fl diphtheria toxin alone. The results showed that for the first 
vaccination study, the group with chitosan alone demonstrated no IgG response as 
expected. The group vaccinated with diphtheria toxin in PBS also showed no IgG 
response until week 6 when a small titre of 20 was detected. The mice vaccinated with 
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diphtheria toxin mixed with chitosan microparticles showed no immune response until 
week 4 but IgG antibody response then increased until week 6 (Lubben et al. 2003). After 
the first study it was concluded association to chitosan microparticles greatly increased 
an immune response (Lubben et al. 2003 and Li et al. 2001). The second study showed 
groups vaccinated with diphtheria toxin alone produce a small immune response. The 
groups vaccinated with diphtheria toxin and chitosan microparticles induced a high 
immune response and dose dependency. The third study concludes the group 
vaccinated with diphtheria toxin in PBS produced a low IgA response, while 
chitosan:diphtheria microparticles produced a significantly higher IgA response. 
However, the antigen utilised in this study (diphtheria toxin) has a stronger affinity to 
produce an immune response than OVA, which may explain the lack of IgA mucosal 
response (Lubben et al. 2003). 
 
Chitosan nanoparticles were prepared via ionotropic gelation, this consisted of chitosan 
concentrations (0.1- 0.5 %) mixed with acetic acid. rHBsAg (Hepatitis B antigen) (4-8 
µg/ml) was dissolved in sodium sulphate (2.5 %) and applied to chitosan/acetic acid 
dropwise whilst stirring. In addition 5 % of PVA (anti-digestive agent) and a few drops of 
pure glycerol was added to increase bond formation between PVA and chitosan. 
Immunisation took place with 4 month old Wister rats. Five groups with six rats in each 
group were immunised orally with the following samples; control (300 µl saline), blank 
PVA- coated chitosan nanoparticles (300 µl of PBS saline), rHBsAg (300 µl with 6 µg 
rHBsAg), PVA coated rHBsAg (300 µl with 6 µg rHBsAg) and rHBsAg (300 µl with 6 µg of 
rHBsAg injected intramuscularly). The results showed PVA-coated rHBsAg chitosan 
nanoparticles produced a significant response almost matching that of the 
intramuscular formulation. This study concluded that this amount of IgG produced was 
protective against hepatitis B (Shrestha and Rath, 2014).  
 
Overall, this chapter shows the chitosan:OVA nanoparticles, which were previously 
shown to have the ability to enhance OVA permeability across Caco-2 intestinal 
epithelial monolayers, do not show a clear ability to induce an immune response in vivo 
(in mice). Therefore, further formulation manipulation is required. For example an 
enteric coating for protection against enzymatic degration and a stronger antigen used, 
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in order to fulfil the potential of chitosan as a suitable material to enhance mucosal 
vaccine delivery.  
 
There were several limitations associated with this part of the study. The vaccination of 
the BALB/c mice was carried out at NIBSC (London) however the chitosan:OVA 
nanoparticles were formulated at the university laboratorys (Lincoln). The chitosan:OVA 
nanoparticles therefore were transported via first class tracking post to NIBSC. This 
created a disadvantage, there was a time lapse of approximately 1-3 days where 
nanoparticle temperature was not regulated, this could have caused aggregation of the 
nanoparticles. This would have had a significant effect upon the nanoparticles and in 
turn the study. 
 
During the in vitro studies the nanoparticles were formulated first before a variety of  
cell studies took place. There was no time lapse between formulation and study. 
However with the in vivo studies there was a time lase of 1-3 days. This would have 
caused aggregation. The packaging was protective but ambient temperature, unlike the 
storage conditions of the nanoparticles which was refrigerator temperature. During this 
time lapse the nanoparticles would have become unstable and possibly aggregated.  
 
Another limitation is the weight of each mouse was not taken into account, meaning the 
larger the mouse the increase in the dosage. The oral polio vaccine dosage is 2 drops 
(0.1ml) in comparison to our nanoparticle dosage of 0.2ml (World Health Organisation, 
2010). This is double the dosage, however this is dependant on the potency of the 
antigen used. The less potent the antigen the higher the dosage would need to be. There 
are three types of polio, the potency of each strain is as follows; type 1 is 800,000, type 
2 is 100,000 and type 3 is 500,000. It is expressed as the amount of virus contained in 
the recommended dose as tissue culture ineffective doses (World Health Organisation, 
2010). The potency of the chitosan:OVA nanoparticles is unknown. OVA, used as the 
antigen, is not as potent as a virus, due to limitations within the lab this was not allowed. 
Although still creates a small immune response seen in figures 5.11 and 5.12.  
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5.5. Conclusion 
Overall the research within this chapter tested the oral vaccine delivery potential of 
chitosan:OVA nanoparticles in mice and tested different immunoglobulins to establish 
mechanistic information. Overall, induction of immune response by chitosan:OVA 
nanoparticles was not convincing. IgG1 response was somewhat higher with the cholera 
toxin added as a second adjuvant which was used to enhance the immune response of 
the vaccine. IgG2a response was low although both groups 3 and 4 displayed no trend. 
Total IgG (dilution 1:10) response was apparent in both groups 3 and 4, interestingly the 
immune response was higher when chitosan:OVA nanoparticles were given without the 
addition of cholera toxin (figure 5.10). IgA response was not obvious. This may be 
attributed to model antigen selection (OVA). Overall, this chapter demonstrates the 
importance of performing in vivo studies for drug delivery formulations by showing that 
the promising in vitro performance of systems does not necessarily reproduce in vivo.  
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Chapter 6 
Summary and Future Directions 
 
 
6.1 Overall Summary 
 
The oral route offers potential for vaccine delivery, achieving mucosal response. The 
mucosal surface of the gastrointestinal tract however presents several barriers to 
achieving mucosal response through oral administration of vaccines. An ideal orally 
administered vaccine delivery system needs to protect the vaccine from physiological 
barriers of the gastrointestinal system, including the harsh biochemical environments 
and ensure that the payload reaches M cells where it induces an immune response.  
 
This work examined a chitosan molecule (chloride salt) for its potential to act as a system 
facilitating vaccine delivery (chapter 3). Work initially assessed the ability of this chitosan 
to complex OVA as a model antigen into nanoparticles. Characterisation studies showed 
chitosan:OVA nanoparticles at 1:1 mass ratio displayed optimal characteristics, such as 
a diameter below 200nm and a positive zeta potential. Chitosan could clearly complex 
with OVA and release it when coming into contact with heparin (negatively charged). 
OVA stability within the chitosan nanoparticles was not compromised due to 
complexation. Some protection from trypsin was evident by chitosan nanoparticles 
however not from exposure to HCl.  
 
The formulation prepared in this work was tested in vitro using Caco-2 monolayers as a 
model of the intestinal epithelium (chapter 4). This is usually a standard approach before 
in vivo studies. Caco-2 studies examined the effect of chitosan:OVA nanoparticles on 
TEER and OVA permeability rather than induction of immune response, (absence of 
relevant immune cells in the Caco-2 intestinal model does not allow that assessment). It 
was found that chitosan:OVA nanoparticles were not toxic to Caco-2 cells, as confirmed 
via MTS and LDH assays and as a result further studies were carried out. During TEER 
studies, reversible decrease in TEER was apparent, which further indicated that the 
chitosan:OVA nanoparticles were not toxic or damaging to the cells or their tight 
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junctions. However a clear effect of TEER is uncertain due to a significant decrease when 
OVA control solution was applied to the cells. Permeability studies showed 
chitosan:OVA nanoparticles produced a higher OVA permeability compared to, 
equivalent concentration of OVA in solution.  
 
The experiments detailed in chapter 5 investigated whether an immune response 
occurred after oral administration of nanoparticles in BALB/s mice. The data revealed 
there was no response, as determined by measuring IgG1, IgG2a or IgA response. 
However, there was some response in total IgG which was in fact higher when no cholera 
toxin was added as an extra adjuvant. More studies are needed to confirm this response, 
including the use of stronger model antigens in order to increase the mucosal immune 
response.    
 
Overall, this work showed that although chitosan is able to complex with protein-based 
therapeutics such as vaccines into nano size entities, which show interesting effects in 
vitro, the desired biological response in vivo may not be adequate and requires 
optimisation. Based on this work, it is not possible to confirm or rule out the potential 
of chitosan for oral vaccine delivery. However, an important conclusion from this study 
is that macromolecular absorption enhancement seen in in vitro intestinal models do 
not reliably predict an in vivo immune response from vaccine delivery systems.  
 
6.2 Future Directions  
 
Oral vaccine delivery is an actively researched area. Types and derivatives of chitosan, 
such as ultra pure chitosan chloride, CMC, TMC and PEGylated chitosan, as well as other 
materials will continue to be investigated for their potential in this field. These systems 
will need to be optimised, via the use of a stronger antigen and a protective enteric 
coating, in order to provide adequate response. This optimisation will have to be specific 
for each antigen. The role of in vitro intestinal models in their current form, including 
Caco-2, in predicting in vivo immune response following vaccine delivery is not clear. 
However, in vitro intestinal models of increased complexity, such as those based on co-
culture of multiple cell types, including immune cells, have been proposed. These 
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models may be more applicable and more useful in predicting the in vivo performance 
of vaccine delivery systems.    
 
 
 
 
 
